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8:00 - 8:45 Registration Open / Arrival Tea and Coffee
8:45 - 9:15 OPENING OF THE CONGRESS
Chair: Alberico Catapano (IT), Gustavs Latkovskis (LV), Bela Merkely (HU), 
Margus Viigimaa (EE)
Welcome speech by Mr. Jüri Ratas, Prime Minister of Republic of Estonia
9:15 - 10:45 PLENARY SESSION I
Lipid management in prevention of cardiovascular disease
Baltic Atherosclerosis Society – European Atherosclerosis Society joint session
Chair: Maciej Banach (PL),  Alberico Catapano (IT), Margus Viigimaa (EE)
9:15 - 9:45 Lipid-lowering therapy: present and future developments. Keynote lecture. 
Alberico Catapano (IT)
9:45 - 10:05 Novel pathways of atherogenesis and challenging therapeutic targets. 
Rimvydas Slapikas (LT)
10:05 - 10:25 Statin intolerance definition, diagnosis and management in 2018. Maciej Banach (PL)
10:25 - 10:45 Current development of lipid management in Baltic countries. Margus Viigimaa (EE)
10:45 - 11:15 Coffee break, Press conference
11:15 - 12:30 PLENARY SESSION II
Cardiovascular risk in diabetes
Chair: Peter Nilsson (SE), Lars Ryden (SE), Vallo Volke (EE)
11:15 - 11:45 Cardiovascular outcome trials in type 2 diabetes. Lessons learned from the perspective 
of a cardiologist. Keynote lecture. Lars Ryden (SE)
11:45 - 12:05 Antidiabetic drugs and cardiovascular risk – endocrinologist’s point of view. Vallo Volke (EE)
12:05 - 12:30 Cardiovascular risk management in diabetes and hypertension. Peter Nilsson (SE)
12:30 - 13:30 Lunch
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 FOURIER: PCSK9 inhibition decreases CV events in high-risk patients. Terje Pedersen (NO)
 Effectiveness and safety of very low LDL-c values with evolocumab: lowest is best. 
Alberico Catapano (IT)
 Which patients could benefit from treatment in clinical practice? Alberico Catapano (IT)
14:20 - 15.05 Berlin-Chemie Menarini
Chair: Margus Viigimaa (EE)
 The newest guidelines on hypertension: focus on tight blood pressure control. 
Margus Viigimaa (EE)
 Uncontrolled hypertension – time to act. Lessons learned from case studies. 
Karlis Trušinskis (LV)
 Discussion
15:10 - 16:40 PLENARY SESSION III - Atherosclerosis and heart
Baltic Atherosclerosis Society – European Society of Cardiology joint session
Chair: Bela Merkely (HU), Aleksandras Laucevicius (LT), Terje Pedersen (NO)
15:10 - 15:30 Lipid-lowering therapy in the future:  Will statins still be the basis? Terje Pedersen (NO)
15:30 - 15:50 Prevention of sudden cardiac death - the role of implantable devices. Bela Merkely (HU)
15:50 - 16:10 Is metabolic syndrome high or moderate cardiovascular (cardiometabolic) risk entity: 
results of Lithuanian High Cardiovascular Risk (LitHiR) programme. 
Aleksandras Laucevicius (LT)
16:10 - 16:30 How to improve BP Control? Novel Initiatives. Serap Erdine (TR)
16:30 - 16:40 Discussion
16:40 - 17:00 Coffee break
17:00 - 18:40 SATELLITE SYMPOSIA
17:00 - 17:45 Boehringer Ingelheim
Anticoagulation Management In Special Situations- Innovative or Conservative Treatment?
 Rewire your thinking on AF ablation. Karlis Trusinskis (LV)
 Improving care decisions after coronary revascularization. Elena Baranova (RUS)
17:50- 18.35 AstraZeneca
Treat to success or treat to failure. What does real life tell us about Type 2 DM?
Karlis Trusinskis (LV), Kristine Ducena (LV)
18:40 - 19:50 PARALLEL SESSION I
Familial hypercholesterolemia
Chair: Gustavs Latkovskis (LV), Michal Vrablik (CZ)
18:40 - 19:00 Three-year experience of the Latvian Registry of Familial Hypercholesterolemia: 
challenges and achievements. Gustavs Latkovskis (LV)
19:00 - 19:20 Familial hypercholesterolemia screening: International and national initiatives.
Žaneta Petrulioniene (LT)
19:20 - 19:40 FH management: expectations and reality. Michal Vrablik (CZ)
19:40 - 19:50 Discussion: Familial Hypercholesterolemia registries in Europe and in Baltic countries
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18:40 - 19:50 PARALLEL SESSION II
Coronary atherosclerosis: physiology and management
Chair: Sergei Nazarenko (EE), Karlis Trušinskis (LV)
18:40 - 19:05 Vascular restoration therapy: the role of intravascular imaging guided plaque 
modification prior drug eluting stent or bioresorbable scaffold implantation. Andrejs 
Erglis (LV)
19:05 - 19:30 Vascular Protection by Factor Xa Inhibition in Patients with Coronary and/or Peripheral 
Artery Disease. Karlis Trusinskis (LV)
19:30 - 19:50 FDG-PET imaging of atherosclerotic plaques. Sergei Nazarenko (EE)
20:00 - 22:00 Welcome reception
SATURDAY, APRIL 7
9:00 - 10:00 PLENARY SESSION IV
Cardiovascular risk factors and management
Chair: Irina Chazova (RU), Iveta Mintale (LV)
9:00 - 9:20 Impact of chronic stress on atherosclerosis process. Dovile Karciauskaite (LT)
9:20 - 9:40 Arterial hypertension and atherosclerosis: data from Russian national registry. 
Irina Chazova (RU)
9:40 - 10:00 Lifestyle management in cardiovascular prevention. Iveta Mintale (LV)
10:00 - 11:20 PLENARY SESSION V
Goals in blood pressure, lipids and glucose. Are we treating well?
Chair: Serap Erdine (TR), Andrejs Erglis (LV), Rimvydas Slapikas (LT)
10:00 - 10:20 Goals in blood pressure. Peter Nilsson (SE)
10:20 - 10:40 Goals in lipids. Gustavs Latkovskis (LV)
10:40 - 11:00 Goals in glucose. Mart Roosimaa (EE)
11:00 - 11:20 Coffee break
11:20 - 11:50 PLENARY SESSION VI
History and future of the Baltic Society of Atherosclerosis. General Assembly
Chair: Zita Kucinskiene (LT), Gustavs Latkovskis (LV), Margus Viigimaa (EE)
11:50 - 12:50 PLENARY SESSION VII
Personalised diagnostics and treatment of atherosclerotic disease
Chair: Valdis Pirags (LV), Peeter Ross (EE)
11:50 - 12:10 From Biobanking to Precision Medicine and beyond: the Estonian Experience. 
Andres Metspalu (EE)
12:10 - 12:30 Using stratified medicine to individualize treatment. Experience from the Latvian 
Genome Data Base. Valdis Pirags (LV)
12:30 - 12:50 Importance of data quality in nation-wide e-health system for personalized medicine 
decision support applications. Peeter Ross (EE)
12:50 - 13:00 Closing remarks
13:00:00 Say Goodbye Coffee
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1. ORAL ABSTRACTS
101. Lipid-lowering therapy: 
present and future developments
Alberico Catapano
Department of Pharmacological and Biomolecular 
Sciences, University of Milan and IRCCS Multimedica
Dyslipidaemias are a major risk factor 
for cardiovascular d isease (CVD), in 
particular high levels of low density 
lipoprotein cholesterol (LDL-C) have been 
associated to a higher cardiovascular 
risk. Reducing LDL-C levels decreases 
the risk of coronary heart disease (CHD), 
and the greater the LDL-C reduction, the 
greater the cardiovascular risk decrease. 
Although statins represent the first line 
lipid-lowering therapy, many patients 
do not reach the recommended goals or 
exhibit adverse side effects leading to 
therapy discontinuation, or continue to 
experience cardiovascular events; even 
in the presence of well controlled LDL-C 
levels, due to Alteration in other lipid/
lipoprotein classes, including triglycerides 
and high-density lipoprotein cholesterol.
These condit ions require further 
therapeutic interventions to achieve the 
recommended lipid goals. Several drugs 
have been developed to address these 
needs. Recent studies have shown that 
the association of ezetimibe with rosuv-
astatin or atorvastatin results in a better 
hypolipemic effect; beside this, PCSK9 
inhibitors significantly reduce LDL-C levels 
and cardiovascular events.
Additional novel approaches to the 
development of drugs that can be used 
either in monotherapy or in combination 
will also be discussed.
102. Novel pathways of 
atherosclerosis and challenging 
therapeutic targets
Rimvydas Slapikas
Lithuanian University of Health Sciences, Kaunas, 
Lithuania
Despite a sign i f icant focus of many 
researchers on atherosclerosis in humans, 
the mechanisms of this disease are still 
not fully understood and atherosclerotic 
vascular disease remains the most impor-
tant cause of myocardial infarction, stroke, 
and heart failure. Numerous studies have 
shown that compendium of elevated serum 
low-density lipoprotein with other major 
risk factors – smoking, hypertension, 
diabetes, obesity and low physical activi-
ties is an ideal environment for the initia-
tion and progression of atherosclerosis. 
However, it is important to defi ne other 
risk factors, which could infl uence the 
process of atherogenesis. TNT (Treating 
to New Targets) and IDEAL (Incremental 
Decrease in Clinical Endpoints  rough 
Aggressive Lipid Lowering) trials suggested 
that despite treatment with high-dose 
atorvastatin and relevant reductions in 
LDL-C levels, the risk of cardiovascular 
events remains high, suggesting the exist-
ence of “residual cholesterol risk” which 
might me further diminished with PCSK9 
(proprotein convertase subtilisin/kexin 
type 9 inhibitors) therapy. Major cardiovas-
cular events were signifi cantly reduced in 
patients without overt hyperlipidemia but 
with elevated high-sensitivity C-reactive 
protein (hs-CRP) levels when treated with 
rosuvastatin in JUPITER trial.  e results 
of the trial confi rmed the relevance of 
“residual infl ammatory risk” and the possi-
bilities as well as the need of additional 
therapies targeting atherosclerosis. Basic 
studies demonstrated that infl ammation 
plays an inevitable role in all the stages of 
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atherosclerosis though its pathogenesis is 
complicated and still remains enigmatic. 
Clinical trials provided evidence for the 
therapeutic values of COX-2 inhibitors, anti-
biotics, low-dose methotrexate and colchi-
cine. Modulation of regulatory proteins 
of infl ammation, including costimulatory 
pathways and cytokines, including inter-
leukin-1, interleukin-6 and tumor necrosis 
factor-a (TNF-a) are explored as therapeutic 
strategies to prevent atherosclerosis.  e 
results of CANTOS (The Canakinumab 
Anti-infl ammatory  rombosis Outcomes 
Study) trial showed that antiinfl ammatory 
therapy targeting the interleukin-1 innate 
immunity pathway with canakinumab at 
a dose of 150 mg every 3 months led to a 
signifi cantly lower rate of recurrent cardio-
vascular events than placebo, independent 
of lipid-level lowering. From biological 
perspective the data of available clinical 
trials demonstrate the need for further 
investigation of infl ammatory mediators 
of atherothrombosis.
103. Statin intolerance definition, 
diagnosis and management in 2018
Maciej Banach
Department of Hypertension, WAM University 
Hospital in Lodz, Medical University of Lodz; Polish 
Mother’s Memorial Hospital Research Institute, 
Lodz; Cardiovascular Research Centre, University of 
Zielona Gora, Zielona Gora, Poland
Statins are the gold standard for managing 
dyslipidemia in patients with elevated 
cardiovascular (CV) risk. Discontinuation 
of statin therapy/therapy non-adherence 
is associated with signifi cant increase in 
CV events.  e most important reasons of 
statin non-adherence are statin-associated 
side eff ects (SASE) – most commonly – 
statin-associated muscle symptoms (SAMS) 
responsible for 95% or more of all SASE. In 
fact, the causality has been confi rmed for 
three of them: myalgia/myopathy, tempo-
rary elevation of alanine aminotransferase 
(ALT) and diabetes mellitus (=new onset 
diabetes mellitus [NODM]).  roughout 
the world patients frequently discontinue 
statin therapy (even 50-60% after 2 years) 
without medical advice due to perceived 
side eff ects, and consequently increase 
their risk for CV events.  us, an important 
issue in the management of patients with 
statin intolerance is the need to avoid statin 
discontinuation. Options include step-by-
step reduction of the statin dose (dechal-
lenge), switching to a diff erent statin, or 
using intermittent dosages (alternate-day 
therapy). Another includes reduction of 
doses and adding of ezetimibe or fi brate 
(especially in case of high triglycerides), 
in severe cases even with application in 
monotherapy. New non-statin agents, as 
well as alternative therapy with nutraceu-
ticals (such as: red yeast rice, phytosterols, 
bergamot, soy products or PUFAs) with or 
without a non-statin drug, may help to 
improve therapy adherence and reduce the 
risk for patients with true statin intoler-
ance. Further studies in statin intolerant 
patients are necessary to confirm the 
eff ectiveness and safety of nutraceuticals 
as well as their eff ect on cardiovascular 
outcomes (CVOTs). In addition, these 
agents will have to be tested in long-term 
randomized controlled trials (RCTs) to 
more defi nitively assess.
104. Current development of lipid 
management in Baltic countries
Margus Viigimaa
North Estonia Medical Centre, Tallinn University of 
Technology, Estonia
 e Baltic countries (Estonia, Latvia, and 
Lithuania) are profoundly affected by 
cardiovascular disease.  erefore, there is 
currently a vital need to implement preven-
tative measures for combating well-known 
CVD risk factors, including high cholesterol. 
However, the usage of lipid-lowering drugs 
in Baltic countries is more than two times 
lower compared to Nordic countries. Vast 
majority of drugs are statins, fi brates and 
unfortunately also ezetimibe are rarely 
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used. Combating dyslipidemia and other 
well-known CVD risk factors such as obesity 
and hypertension is vital to reduce the 
exceptionally high risk for CVD mortality 
seen in the Baltic countries.
We have performed the DYSIS study 
with the aim of aim to analyse the dyslipi-
demia treatment in a large dataset from the 
Baltic countries. Patients in primary care 
centers across the Baltic countries were 
enrolled into the cross-sectional, observa-
tional study. We enrolled 1797 patients ≥45 
years old treated with statins for at least 
three months. Our fi ndings indicate that 
many statin-treated patients in Estonia, 
Latvia and Lithuania did not meet target 
lipid levels and had a very high risk of CVD. 
Multivariate analyses indicated that a BMI 
≥ 30 kg/m2 (OR, 2.12; 95% CI, 1.45–3.08) and 
hypertension (OR, 2.43; 95% CI, 1.1 6–5.10) 
were strongly associated with dyslipidemia 
(involving all three lipids) during statin 
therapy while age ≥70 years (OR, 0.63; 95% 
CI, 0.42–0.94) and female gender (OR, 0.48; 
95% CI, 0.33–0.68) conferred reduced risk. 
LDL-C was not at target level for 80.7%; low 
HDL-C levels were observed for 26.0%, and 
elevated TG levels were found in 35.0% of 
all patients.
REFERENCE  
Viigimaa M, Erglis A, Latkovskis G, Mäeots E, Petrulionienė Z, 
Slapikas R, Gocentiene A, Bramlage P, Brudi P. Prevalence of 
dyslipidemia in statin-treated patients in the Baltic states 
(Estonia, Latvia, and Lithuania): Results of the Dyslipidemia 
International Study (DYSIS). Medicina 2014;50(1):44-53.
105. Cardiovascular outcome trials 
in type 2 diabetes -
Lessons learned from the 
perspective of a cardiologist
Lars Rydén
Department of Medicine K2, Karolinska Institutet, 
Stockholm, Sweden
Cardiovascular disease is a major threat to 
people with diabetes. Attempts have since 
long been made to lower the cardiovas-
cular risk by means of glucose lowering 
treatment. Initially it seemed that this 
possibility was an option but subsequent 
trials could not verify the original observa-
tions and concern was raised that some 
glucose lowering drugs may indeed cause 
cardiovascular harm.  is caused medical 
product agencies in the US and Europe 
to require major outcome trials before 
accepting new glucose lowering drugs. 
 e least requirement was non-inferiority 
compared to existing treatment modalities.
A large number of cardiovascular 
outcome t r i a l s  (C VOT )  h ave  b een 
performed or are ongoing including 
more that 100 000 patients with type 2 
diabetes. Drug classes investigated are 
basal insulin, Di peptidyl peptidase-4 
inhibitors (DPP-4 inhib), glucagon-like 
peptide-1 receptor agonists (GLP-1RA) 
and sodium-glucose co-transporter-2 
inhibitors (SGLT-2) inhibitors.
The lecture will discuss these trials 
and reasons why some of them ended with 
neutral results (non-inferiority). In contrast 
the surprising and highly rewarding impact 
of SGLT-2 inhibitors (EMPA-REG OUTCOME 
and CANVAS trials) and GLP-1 receptor 
agonists (LEADER and SUSTAIN-6, trials) 
have led to a shift in the way CVOTs are 
viewed.  ese trials have led to a growing 
appreciation that type 2 diabetes is a disease 
that extends beyond hyperglycaemia.  e so 
far rather glucocentric treatment approach 
needs to be abandoned and numerous other 
considerations taken into account when 
considering the best management.
The precise mechanisms by which 
SGLT-2 inhibitors and GLP-1RAs lead to 
beneficial effects on the cardiovascular 
system are still not fully understood, and 
the impact of the new data on diabetes 
management is a topic of intense debate.
The audience will be brought on a 
journey through a number of lessons on 
diabetes care strategies from a cardi-
ologist ’s perspective, beginning with 
the history of glucose-lowering trials, 
progressing to recent CVOTs in diabetes, 
and concluding with some recommenda-
tions for changes in diabetes care.
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106. Antidiabetic drugs 
and cardiovascular risk – 
endocrinologist’s point of view
Vallo Volke
Tartu University, Tartu University Hospital
Cardiovascular complications of hyper-
glycemia are among the most important 
concerns of patients with diabetes. Until 
recently the best ev idence indicated 
that good glycemic control of diabetes 
can postpone cardiovascular disease, 
but treatment needed to be in place, 
literally said, for decades. Clinical trials 
aiming at very strict glycemic control 
resulted in disappointing lack of effect 
on macrovascular complications, or clear 
harm. Surprisingly enough, the game-
changing results were obtained from trials 
primarily designed to prove cardiovascular 
safety of new diabetes drugs. Collectively, 
we have now 3 drugs/drug classes with 
proven cardiovascular benefit. One must 
not forget the first and oldest of these, 
pioglitazone. While the f irst study of 
pioglitazone was not able to demonstrate 
benefit in terms of primary outcome, 
the recent study in stroke patients was 
clearly positive.
We are now left with couple of ques-
tions which are worth further clarifi cation.
1. Where will be the optimal position of 
the drugs with CV benefit?
2. In pat ients w ith substant ia l  C V 
morbidity, will metfromin will remain 
the first choice?
3. What will be the optimal strategy 
combining the drugs with CV benefit, 
will some combinations result in addi-
tive efficacy?
With all of the positive results we still 
must recognize the potential side-effects 
of the drugs.
From that viewpoint, it seems that 
pioglitazone has the most problematic 
side-effect profile and GLP-1 receptor 
agonists have so far demonstrated surpris-
ingly few safety problems.
To conclude, we are now in a posi-
tion where we can provide better value 
for our patients with high CV risk and, 
sometimes, build a more tailor –made 
treatment schemes.
107. Cardiovascular risk 
management in diabetes and 
hypertension
Peter M Nilsson
Lund University, Skåne University Hospital, Malmö, 
Sweden
Hypertension in diabetes is a common, 
treatable and cost-effective risk factor 
to intervene on, based on evidence from 
many randomized controlled studies, 
as recently summarized in a number of 
important meta-analyses and reviews 
[1-3]. Most antihypertensive drugs can be 
used, preferred as combination therapy, 
to prevent the patients from micro- and 
macrovascular complications, as well as 
renal impairment and cognitive decline. 
An additional benefi t is to reduce the risk 
of diabetic eye complications and retin-
opathy according to the UKPDS study. An 
interesting aspect is the timing of drug 
intake. In one Danish study, the intake of 
antihypertensive drugs in patients with 
type 2 diabetes and non-dipping was more 
eff ective for 24-h blood pressure control if 
randomized to bed-time versus morning 
intake [4].
A sensitive and much debated issue is 
the blood pressure (BP) goal in patients 
with type 2 diabetes. European guidelines 
from ESH/ESC 2013 have recommended 
a BP target below 140/85 mmHg, but the 
American Diabetes Association (ADA) 
recommends (2018) a BP goal below 140/90 
mmHg in most such patients, but less than 
130/80 mmHg in subgroups ( younger 
patients tolerant to BP lowering without 
adverse effects) [5]. It should be noted 
that the ADA disregards the much debated 
SPRINT trial because it did not include any 
patients with diabetes at all. Recently the 
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American Heart Association, together with 
other US organisations, have proposed a 
new defi nition of hypertension (> 130/80 
mmHg) in all subjects with elevated BP, 
irrespective of diabetes status.  ese organi-
sations also recommend the lowering of 
BP to below 130/80 mmHg in all patients, 
including diabetes patients [6]. During 2018, 
a new set of European guidelines have been 
announced to be published.
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108. Lipid-lowering therapy in 
the future: Will statins still be the 
basis?
Terje R. Pedersen
Oslo University Hospital, Oslo, Norway
Since 1994 statins have been established 
as the main class of drugs for prevention 
of atherosclerotic cardiovascular disease 
(ASCVD). Until recently other classes of 
lipid interventions have played a relatively 
small part. Fibrates are losing their role as 
preventive treatment modality with only 
small effect on clinical events in rand-
omized trials. Ezetimibe has rarely been 
used in more than 5% of patients with 
established ASCVD in most countries but 
this may change when ezetimibe comes 
off patent and the price will fall. Recently 
inhibitors of PCSK9 have been introduced 
as a powerful treatment modality to lower 
LDL cholesterol, but the relatively high 
cost has so far prevented widespread use. 
In the next future inclisiran and bempe-
doic acid will likely be introduced as other 
effective alternatives. In the meantime 
statins have come under attack because 
of an increasing reputation of causing side 
effects, in particular muscle problems. 
However, the statin class remains the 
best documented treatment in current 
cardiovascular medicine with 28+ large 
randomized clinical trials. In addition new 
lipid interventions have been tested in 
patients who have been receiving a back-
ground therapy with statins. In contrast 
to medical practice double-blinded trials 
with statins have not shown an excess 
of myopathy or muscle pain compared 
with placebo. On the other hand there is 
evidence from clinical trials that statins 
may increase the risk of type 2 diabetes. 
Although the risk is small, patients with 
risk factors for developing type 2 diabetes 
might experience an increase in levels of 
HbA1c into the diabetic range. This does 
not counteract the beneficial effect on 
ASCVD prevention. The merits of statins 
from clinical trials together with their 
decreasing price level confirm their role 
as the fundament of ASCVD prevention, 
both in primary and secondary prevention.
109. Prevention of sudden cardiac 
death - the role of implantable 
devices
Bela Merkely
Heart and Vascular Center, Semmelweis University, 
Budapest
Sudden card iac death (SCD) i s st i l l 
accountable for approximately 25% of 17 
million cardiovascular deaths per, inspite 
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of continously improving prevalence. 
Risk of SCD increases with aging, most 
important etiological factors are ischemic 
heart disease, heart failure and struc-
tural heart diseases in the elderly, while 
chenellopathies, cardiopathies are the 
most prevalent causes among the young.
Implantable cardioverter defibrilla-
tors are used in primary and secondary 
prevention of SCD for more than 30 years. 
Nowadays transvenous systems are the 
most widespread, they can be combined 
with cardiac resynchronization therapy 
(CRT) as well.
ICD therapy was first introduced for 
secondary prevention of SCD. Among 
patients with history of aborted SCD, 
ventricular fibrillation (VF) or haemodi-
namically unstable ventricular tachycardia 
( VT ) ICD therapy for more beneficial 
in reducing arrythmogenic death than 
antiarrythmic medications based upon 
results from AVID, CIDS and CASH trials.
ICD therapy is effective in the primary 
prevention of SCD as well, when no malig-
nant ventricular arrythmia is present in 
the previous history, but the risk is highly 
elevated. The most common such popula-
tion is heart failure patients with severly 
reduced ejection fraction. The optimal 
medical therapy of heart failure signifi-
cantly decreases the risk of SCD, however 
in MADIT-II and SCD-HeFT trials further 
decrease in arrythmogenic and all-cause 
mortality was observed in both ischemic 
and dilated cardiomyopathy.
Novel direction of device develop-
ment is subcutaneous ICD (S-ICD), where 
electrodes are located subcutaneously 
encompassing the heart, outside the 
thorax. The main advantage of S-ICD is 
the lack of transvenous intracardiac elec-
trodes, and thus the freedom from elec-
trodes complications. S-ICD is effctive in 
prevention of SCD, therefore can be a real 
alternative for transvenous ICD in patients 
not requiring bradycardia-, biventricular-, 
or antitachycardia-pacing (ATP).
Wearable cardioverter-defibrillator 
(WCD) is an external ICD integrated into a 
vest, which might be beneficial for patients 
temporarily increased risk of SCD, with 
chance to recovery (acute myocarditis, 
peripartum cardiomyopathy, bridge to 
transplant).
110. Is metabolic syndrome high 
or moderate cardiovascular 
(cardiometabolic) risk entity: 
results of Lithuanian High 
Cardiovascular Risk (LitHiR) 
programme
Aleksandras Laucevičius, Ligita 
Ryliskyte, Svetlana Solovjova, Jolita 
Badariene, Jelena Celutkienė, Roma 
Puronaite, Ieva Slivovskaja, Egidija 
Rinkuniene, Rokas Navickas
Vilnius University Hospital Santariškių Klinikos, 
Vilnius
According to the European guidelines for 
hypertension and cardiovascular (CV ) 
prevention, metabolic syndrome (MetS) 
is considered to ref lect moderate CV 
risk. It is estimated that the presence 
of MetS means 5 times elevated risk of 
development of diabetes and 1.5-2 times 
elevated CV risk.
National Lithuanian High Cardiovas-
cular Risk (LitHiR) prevention programme 
is running in Lithuania from 2006. Two 
level approach is applied: primary level 
health care institutions (PHCI) and special-
ized cardiovascular prevention units 
(CVPU). Subjects with high CV risk are 
assessed in detail in CVPU. Among other 
subjects, individuals with MetS (modified 
NCEP ATP III) are identified and referred 
to a specialized CVPU. These subjects 
are reassessed in the CVPU in order to 
re-assign them to moderate or high CV 
categories.
We analyzed the data obtained from 
5691 subjects with MetS. Number of 
components of MetS was distributed as 
follows: 3 of 5 components were present in 
42%, 4 of 5 – in 38.2% and 5 of 5 – in 19.8% 
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of subjects. Apart from the components 
of MetS, additional CV risk factors were 
estimated. Elevated LDL Ch > 3 mmol/l 
was found in 85.5%, elevated hsCRP (> 3) 
– in 34.1%, microalbuminuria – in 7.4%, 
left ventricular (LV ) diastolic dysfunc-
tion in 63.4%, LV hypertrophy - in 49.8%, 
enlarged left atrium – in 48.7%, presence 
of atherosclerotic plaques in catid arteries 
- in 40.3%, carotid-femoral PWV > 10m/s 
– in 18.6%. The MetS subjects who, in 
addition to the classical MetS components, 
had at least one additional risk factor, 
mentioned above, were reclassified by us 
from moderate to high CV risk. In order 
to distinguish these patients from the 
moderate CV risk subjects, we propose to 
use the term “elevated cardiometabolic 
risk subjects.”
Furthermore, in the cohort of 170 
subjects with MetS, we examined the the 
influence of the aerobic physical training 
on the dynamics of aortic stiffness. In 75 
of these subjects, who underwent a heart 
rate controlled aerobic physical training, 
a statistically significant improvement 
of aortic stiffness ( lowering of carotid-
femoral pulse wave velocity) was observed. 
This positive dynamic was not present in 
the control group of 75 subjects for whom 
only recommendations for physical activity 
were provided. This result suggests that 
a supervised aerobic training is a reliable 
measure for lowering cardiometabolic risk.
111. How To Improve Blood 
Pressure Control? Novel Initiatives
Serap Erdine
Marmara University,Hypertension Unit, Istanbul, 
Turkey
Turkish Society of Hypertension And Atherosclerosis
The primary aim of antihypertensive 
treatment is to reduce blood pressure 
(BP) to guideline-recommended targets 
in order to maximise the long-term 
reduction in the risk of cardiovascular 
(CV ) events. Nonetheless, despite the 
well-established relationship between 
hypertension and the increased risk of 
CV morbidity and mortality, BP control 
rates remain suboptimal. In developed 
countries, estimates show that only 11% 
and 17% of male and female hypertensive 
patients, respectively, are achieving BP 
control. In Europe, data from the Cardio-
Monitor survey of physician visits has 
indicated that the proportion of hyper-
tensive patients achieving BP control 
varied from 31–46%.Suboptimal BP control 
rates impose a substantial global health 
burden. An estimated 7.6 million prema-
ture deaths worldwide were attributed 
to hypertension, with approximately 17% 
of all disability adjusted life years lost 
in European countries being due to CV 
disease. In addition, uncontrolled BP also 
contributes to a significant burden on the 
economy as the annual cost of CV disease 
in the EU is an estimated €192 billion.
Evaluation of predictors of CVD is 
essential for early detection, prevention, 
and treatment. Modern guidelines on 
screening, detection, evaluation, and treat-
ment of hypertension repeatedly stress the 
importance of appropriate BP control in 
high-risk patients. An observational study 
from Turkey, TRES-1 showed that, blood 
pressure control was poorer in patients 
with 3 or more risk factors or diabetes 
mellitus compared to patients with no 
additional risk factors or 1-2 risk factors.
Poor patient compliance and adher-
ence with prescribed antihypertensive 
medication makes a major contribution 
to the development of suboptimal blood 
pressure (BP) control. The asymptomatic 
nature of hypertension, side effects of 
medication, treatment complexity and 
high pill burdens all have a negative impact 
on patient compliance. It is important to 
address the issue of poor patient compli-
ance as studies have shown that good 
compliance is associated with improve-
ment of BP control and positive health 
outcomes.
Therapeutic adherence is a multi-
factorial issue inf luenced by patient-, 
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physician-, and therapy-related factors. 
Patient-related factors include demo-
graphic characteristics (e.g., age, gender, 
socioeconomic status), cognitive function 
(e.g., dementia, depression), patient’s lack 
of insight in to the illness and missed 
appointments.
Retrospective analyses have suggested 
that about 40% of newly d iagnosed 
patients with hypertension discontinue 
their antihypertensive therapy in the first 
year of treatment. In addition, according 
to the WHO report on adherence to 
long-term therapies, >50% of the patients 
treated for hypertension drop out of care 
entirely within a year of diagnosis and, of 
those who remain under medical supervi-
sion, only about 50% take ≥80% of their 
prescribed medication.
There is growing evidence that physi-
cian inertia is also an important cause of 
poor BP control. Physician can contribute 
to the problem by not explaining the 
regimen, effects and side effects properly, 
not learning patient’s characteristics and 
lifestyle, poor knowledge about the cost 
of medications and insurance coverage of 
available formularies, failing in patient-
physician conversation and some physi-
cians are willing to treat hypertension 
aggressively.
Adherent patients have a lower predic-
tive relative risk of adverse cardiovascular 
outcomes compared with these who 
were non-adherent and good compli-
ance has been shown to be associated 
with successful BP control. There are 
various ways in which compliance may 
be improved, such as raising awareness of 
the dangers of hypertension, improving 
patient education, encouraging patients 
to become more accountable for their 
own health, and treatment simplification.
Electronic communication with the 
physician (use of telemetry for transmis-
sion of recorded home values, maintaining 
contact between  patients and physicians) 
may provide an acceptable alternative 
to improve adherence to treatment. 
Providing continuous education and infor-
mation on disease, treatment, and objec-
tives (information material, programmed 
learning,computer-aided counsell ing) 
is also crucial for improving BP control.
Panaceastar is the first and unique 
platform in medicine which establishes 
link between key opinion leaders, physi-
cians and patients via internet.
Panaceastar targets, control and treat-
ment of acute and chronic diseases by 
offering comprehensive, high quality 
customized solutions to the individual 
needs of each patient, including elderly, 
ch i ldren and adolescents, pregnant 
women, oncologic patients and patients 
with stroke.
Panaceastar provides live video consul-
tation with consecutive translation oppor-
tunity in many languages and with sign 
language for deaf patients.
Panaceastar respects the pr ivacy 
of every person and is committed to 
protecting all the Personnel and Medical 
Information.
One of the most important tasks of 
Panaceastar is to increase the awareness 
and prevent the chronic diseases and its 
risks by giving advices on lifestyle changes 
to improve the quality of life.
In conclusion,control of BP remains a 
challenging issue and novel strategies may 
become a viable option for those patients 
with uncontrolled hypertension.
112. Three-year experience of 
the Latvian Registry of Familial 
Hypercholesterolemia: challenges 
and achievements
Gustavs Latkovskis
Latvian Institute of Cardiology and Regenerative 
Medicine, Riga, Latvia
Latvian Registry of Familial Hypercho-
lesterolemia (FH) was establ ished in 
February 2015 as a research project within 
frames of the Latv ian State Research 
Programme BIOMEDICINE, and it i s 
carried out by the Latvian Institute of 
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Cardiology and Regenerative Medicine, 
University of Latvia in collaboration with 
Pauls Stradins Clinical University Hospital. 
The aim of the Registry was to improve 
diagnosis and management of FH patients 
in order to cost-effectively prevent cardio-
vascular morbidity and mortality among 
these very high risk patients.
Before year 2015 very few FH cases 
were recognized by physicians in Latvia 
due to very low professional awareness of 
the disease despite the fact that estimated 
number of such patients was at least 8000 
in the whole country. Public awareness 
was virtually non-existent.
The activities of the Registry first and 
foremost included education of cardiolo-
gists, general practitioners, endocrinolo-
gists, internists and other specialists on 
the clinical signs and diagnosis of FH. The 
public awareness was effectively raised in 
close collaboration with cardiovascular 
patient organization ParSirdi.lv. An impor-
tant key to the success was involvement of 
a dedicated team consisting of enthusiastic 
cardiologists and young doctors.
All patients referred to the Registry 
were evaluated according to the Dutch 
Lipid Clinic Network criteria. Manage-
ment of patients included further risk 
stratification and lipid-lowering as well 
as cascade screening that was initiated 
for the first-degree relatives in cases of 
probable or definite FH of index patients. 
Within three years 416 individuals have 
been included in the database, and 176 of 
them have been diagnosed with FH. Thus, 
according to our estimation, approxi-
mately 2.2% of all FH patients in Latvia 
have been diagnosed at the Registry by 
the end of December 2017. Another 151 
patients have possible FH, and a proportion 
may be reclassified to probable or definite 
FH after further evaluation. All patients 
were consulted regarding further manage-
ment with follow-up recommendations. 
Collaboration with general practitioners 
was set as a top priority.
Regrettably, our data also revealed that 
management of most FH patients before 
involvement in the Registry was far from 
optimal. Half (46%) of FH patients were not 
on any kind of lipid-lowering therapy at 
the time of inclusion in the Registry, and 
only 23% were on maximal atorvastatin 
or rosuvastatin doses despite mean age of 
51.4 years. Only 3% and 6% of high- and 
very high-risk FH patients had their LDL-C 
levels below goal before inclusion in the 
Registry. One third (36%) had history 
of premature coronary heart disease. 
The youngest individual with diagnosed 
asymptomatic coronary atherosclerosis 
was 27 years old. These and other obser-
vations of the Latvian Registry of FH are 
convincing proofs to our professional 
community how critical is the need for 
such registries and specialized care of 
FH patients. State funds should clearly 
be allotted for these purposes.
113. Familial hypercholesterolemia 
screening: International and 
national initiatives
Zaneta Petrulioniene
Vilnius University Medical faculty, Vilnius University 
Hospital Santaros Clinics
Familial hypercholesterolemia (FH) is 
commonest co-dominantly inherited 
condition. Mutations in one of three 
genes result in life-long elevations in LDL 
cholesterol and development of premature 
atherosclerotic cardiovascular disease. 
FH is underdiagnosed and undertreated 
in most countries. There is urgent need 
to improve diagnostics and treatment of 
FH in Baltic countries, create national 
registries and join international initia-
tives. Lithuania is among participants of 
EAS Familial Studies Collaboration (FHSC) 
project. Main rationale and design of the 
global EAS-FHSC initiative of European 
Society of Atherosclerosis is pool ing 
and expanding registr ies of famil ia l 
hypercholesterolemia to assess gaps in 
care and improve disease management 
and outcomes. Agreements with National 
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Coordinators have already been signed; 
preparation of documents for regional 
Biomedical Research Ethics committee, 
close collaboration with coordinating 
center in Imperial College London has 
been successfully started. Another inter-
national activ ity is Screening Project 
for Famil ial Hypercholesterolemia in 
Central, Southern and Eastern Europe 
(ScreenProFH). Certificate of National 
Coordinator has already been signed, 
preliminary data have been published. 
Textbook “Familial hypercholesterolemia” 
(written by Richard Cask) has been trans-
lated to many languages (to Lithuanian as 
well). It will help to increase educational 
level of knowledge about FH.
At the national level Competence centre 
of Lipidology (member of MetabERN; 
network coordinator Maurizio Scarpa) 
has been established at Vilnius University 
Hospital Santaros Clinics (together with 
Centre of Pediatrics and Coordinating 
Centre of Children’s rare Diseases). Meta-
bERN (the European Reference Network 
for Hereditary Metabolic Diseases) is one 
of the 23 approved European Reference 
Networks For Rare Diseases. MetabERN 
gives excellent possibility for cardiolo-
gists, pediatricians and other specialists 
to work together in the field of hereditary 
metabolic diseases and dyslipidemia.
Screening of familial hypercholes-
terolemia and FH registry in Lithuania 
has been started on the basis of nation-
wide cardiovascular primary prevention 
programme. There are thousands of lipi-
dograms of the middle-aged Lithuanian 
men and women in the database for the 
detailed lipid profile analysis. Cases of 
severe dyslipidaemia and possible FH 
are extracted and analyzed. Another 
important national activity is creation of 
FH databases and FH follow-up systems 
in Vilnius University Hospital Santaros 
Clinics Electronic case reports system 
(with data protection): one database is 
created under supervision of Compe-
tence center of Lipidology and dedicated 
for adult and pediatric patients with 
rare and severe dyslipidaemia, another 
database - for adult patients with early 
acute coronary syndrome and possible 
FH. Delegated users with their passwords 
and usernames are allowed to connect 
those systems. Cascade screening of index 
case families has already been started. 
Cardiologists, pediatricians, geneticists, 
apheresis special ists, family doctors, 
laboratory diagnostic specialists, derma-
tologists and even plastic surgeons (when 
needed) are involved in the management 
of FH patients. Vilnius University Hospital 
Santaros Clinics is coordinating center for 
FH screening initiative. Dutch Lipid Clinic 
Network criteria are recommended and 
applied for the FH index case diagnosis. 
Lipid lowering drugs (statins, ezetimibe, 
fibrates) are available and reimbursed in 
Lithuania. PCSK9 inhibitors are available, 
but not reimbursed. Lithuania actively 
participated in PCSK9 trials: ODDYSSEY 
and FOURIER. There are several apheresis 
centres in Lithuania, but LDL apheresis 
is not available currently and not reim-
bursed. Genetic testing of FH has been 
successfully implemented and reimbursed 
in Vilnius University Hospital Santaros 
Clinics. Lithuanian Heart Association and 
Lithuanian Society of Cardiology take 
active part in national FH initiatives.
114. FH management: expectations 
and reality
Michal Vrablik1, Freiberger T2, Raslova K3, 
Vohnout B4, Vaclova M1, Blaha V5, 
Soska V6, Kyselak O6, Urbanek R7
1 Charles University, Prague, Czech Rep, 2 Centre for 
cardiovascular and transplant surgery, Brno, Czech 
Rep., 3 Metabolic Centre of Dr. Katarina Raslova, 
Bratislava, Slovak Rep., 4 Slovak Health University, 
Bratislava, Slovak Rep., 5 Charles University, Hradec 
Kralove, Czech Rep., 6 Masaryk University, Brno, 
Czech Rep., 7 ORMIGA Center, Zlin, Czech Rep.
Familial hypercholesterolemia is the most 
frequent genetic disorder associated with 
premature atherosclerotic cardiovascular 
disease (CVD). Several international and 
Eesti Arst 2018;97(Lisa1):1–48 21
7TH BALTIC ATHEROSCLEROSIS SOCIET Y CONGRESS
national guidelines have emphasised the 
need for early identification and aggres-
sive management of FH, which have been 
proven effective in reducing CVD risk.
Despite the vast evidence and guidance, 
identification rate of FH individuals in 
most populations remains low and attain-
ment of therapeutic goals is suboptimal. 
Thus, we designed non-interventional, 
retrospective, open-label, multicentre 
disease registry for patients with hete-
rozygous familial hypercholesterolemia 
in the Czech Republic and Slovakia (the 
PLANET registry).
The aim of the PLANET registry was to 
assess the attainment of therapeutic target 
LDL-C level in the settings of everyday 
medical practice. The second goal was 
to characterize lipid-lowering therapy 
patterns in FH patients in the real life 
and to characterize cardiovascular events 
observed in this patient population.
1755 pat ients were enrol led and 
analysed. 1421 patients were enrolled 
in 24 Czech sites and 334 patients were 
enrolled in 8 Slovak sites, all members of 
the nationwide network of specialized 
FH (MedPed) centres. The mean LDL-C 
observed in all 1755 subjects was 3.52 
mmol/l (SD=1.51). LDL-C in the subgroup 
with target value ≤ 1.8 mmol/l resp. ≤ 2.5 
mmol/l was 3.32 mmol/l (SD=1.48) resp. 
3.67 mmol/l (SD=1.52). The mean in the 
subgroup with attainment of target value 
resp. without attainment of target value 
was 1.80 mmol/ l (SD=0.54) resp. 3.82 
mmol/l (SD= 1.42). Participating patients 
were treated with monotherapy (49%) or 
combination of lipid lowering medications 
(43%). Some of observed subjects were 
newly diagnosed patients (8%) without 
therapy to date. Statins were used by 1578 
patients (98%). At least one cardiovascular 
event experienced 16.8% patients from the 
PLANET registry population (n = 1739).
The PLANET registry documents insuf-
ficient intensity of management of the FH 
patients whose LDL-C target values attain-
ment remains low. Despite high penetra-
tion of statin therapy in the population 
studied, we have documented inadequate 
dose titration and lack of combination 
therapy use. Periodical evaluation of 
treatment patterns highlighting gaps 
in the management of FH patients is an 
important tool to improve standards of 
care even in the specialized care setting.
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115. Vascular restoration therapy: 
the role of intravascular imaging 
guided plaque modification prior 
drug eluting stent or bioresorbable 
scaffold implantation
Andrejs Erglis
Pauls Stradins Clinical University Hospital, University 
of Latvia, Riga, Latvia
Second-generation drug-eluting stents 
(DES) have revolutionezed treatment of 
obstructive coronary artery disease by 
reducing the rate of restenosis and the 
need for repeat revascularization when 
compared to bare-metal or fi rst-generation 
DES. Bioresorbable vascular scaff old (BVS) 
represents a new concept of providing 
transient vessel support with drug delivery 
capability but theoretically without the 
long-term limitations of metallic DES.
The left main (LM) – the most proximal 
part of the left coronary artery – is the 
most important structure in the human 
arterial vascular tree. The majority of 
patients with LM disease are symptomatic 
and have a very high risk of major cardio-
vascular events. During the last decade, 
many technological improvements have 
been made for percutaneous coronary 
intervention (PCI) and many studies have 
been conducted to evaluate the efficacy 
of different revascularisation methods in 
patients with LM lesions.
Since 2002 we have enrolled all consec-
utive patients with LM stenosis who 
underwent PCI at the Latvian Centre of 
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Cardiology in the registry to evaluate the 
real-world outcomes of LM PCI.  e analysis 
of 965 patients showed that one year 
cardiovascular survival rate was higher 
in patients with intravascular ultrasound 
( IVUS) guided LM stenting compared 
with patients without IVUS guided LM 
stenting. One year total and cardiovascular 
survival rates were signifi cantly higher in 
patients with plaque modifi cation with 
cutting balloon before stent implantation 
compared with others. In the latest Euro-
pean guidelines on myocardial revasculari-
zation the indication of PCI of LM with low 
or moderate angiographic risk has been 
equated to coronary artery bypass grafting, 
however the appropriateness of PCI in high 
risk LM anatomy, including true bifurcation 
lesions requiring double stenting, remains 
an area of controversy. Our hypothesis is 
that applying modern diagnostic (intravas-
cular imaging guiding and optimization) 
and treatment (plaque pre-treatment prior 
stenting, new generation DES, BVS, adjunc-
tive pharmacotherapy) strategies could 
improve PCI outcomes in patients with 
high risk anatomy.  erefore, recently we 
initiated a pilot, prospective, consecutive, 
one centre registry analysing feasibility 
of IVUS-guided and optical coherence 
tomography-optimized two stent tech-
nique using DES from LM to the main 
branch and BVS in the side branch for the 
treatment of distal LM true bifurcation 
stenosis.  e study is on-going and results 
will be presented.
116. Vascular Protection by Factor 
Xa Inhibition in Patients with 
Coronary and/or Peripheral Artery 
Disease
Karlis Trusinskis, MD, PhD
Stradins Clinical University Hospital, Riga, Latvia
Dual antiplatelet therapy has been ACS 
pharmacological strategy for decades. 
Dual pathway inhibit ion concept by 
blocking Xa factor on the top inhibited 
platelets was  successfully tested in ATLAS 
ACS-TIMI trial.  Mortality and morbidity 
rates  in patients with multifocal athero-
sclerosis are still  high. Recent trial data 
showed effectiveness of combination of 
vascular dose of rivaroxaban and aspirin 
stable coronary artery disease and periph-
eral artery disease patients.
117. Role of 18F-FDG-PET/CT in 
Management of Atherosclerotic 
Plaque: Current Evidence
Sergei Nazarenko
North Estonia Medical Centre, Department of 
Nuclear Medicine and PET
Objective: Management of atherosclerotic 
plaque and inf lammation stays in the 
focus of clinical management of patients 
with atherosclerosis and dyslipidemias. 
Increasing availability of 18F-FDG-PET/CT 
in standard hospital settings for different 
clinical applications has raised the interest 
in possible role of this method in detection 
and assessment of inflammatory capture 
of atherosclerotic plaque.
Methods: In our report, we provide an 
overv iew about current ev idence on 
18F-FDG in management of atheroscle-
rotic plaque.
Results: Use of 18-F-FDG-PET/CT is usually 
not included into current guidelines for 
clinical practice. This is also the case with 
2016 ESC/EAS Guidelines for the Manage-
ment of Dyslipidaemias, and with the 2016 
European Guidelines on cardiovascular 
disease prevention in clinical practice. 
However, a number of publications is 
dedicated to this topic.
Importance of this issue is emphasized 
by the clinical reality where 18F-FDG-PET/ 
CT studies may be performed not only 
as a dedicated study in patients with 
atherosclerosis or dyslipidaemias, but 
inf lammatory atherosclerotic plaques 
may present them as occasional findings 
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on 18F-FDG-PET/CT studies in patients 
with oncological or neurological problems.
Available data provide useful hints for 
the interpretation of 18FDG uptake in 
vascular wall. At the same time, available 
data point to the need of further system-
atic studies of the role of 18F-FDG-PET/CT 
in assessment of atherosclerotic plaque, 
as well as to the need of fine tuning of 
PET/CT studies for the assessment of an 
atherosclerotic plaque.
Conclusions: Role of 18F-FDG-PET/CT in 
assessment and management of athero-
sclerotic plaque cannot be disregarded due 
to increasing availability of this method. 
It may be used for detection of infl amma-
tory processes, for evaluation of prognosis 
and treatment results. And it should be 
correctly reported when occasionally 
detected in imaging due to other diseases.
118. Impact of chronic stress on 
atherosclerosis process
Dovilė Karčiauskaitė, Neringa Burokienė, 
Reda Matuzevičienė, Asta Mažeikienė, 
Zita Aušrelė Kučinskienė
Vilnius University, Faculty of Medicine, Institute of 
Biomedical Sciences
Atherosclerotic cardiovascular diseases 
remain the major cause of death world-
wide. Since the death rates from cardio-
vascular diseases are generally higher 
in Lithuania than in Western European 
countries and traditional risk factors not 
always explain this higher morbidity, 
other atherosclerosis risk factors have 
to be considered. Psychological factors 
have significant impact on pathogenesis, 
progression and complications of athero-
sclerosis, but mechanisms underlying 
these associations are not completely 
clear. In our work we sought to examine 
effects implicated by chronic psycho-
logical stress on several pathogenetic 
pathways: dyslipidemia, oxidative stress 
and inf lammation. The evaluation of 
chronic stress was made not only by 
using specific questionnaires, but also 
by measuring cortisol concentration 
in hair, which ref lects perceived stress 
over certain period of time. Malondial-
dehyde, total antioxidant activity and 
concentration of carotenoids in blood 
were measured as biomarkers of oxida-
tive stress. Inf lammation was evaluated 
by a high sensitivity C-reactive protein, 
interleukin-6 and cyclophilin A.
In our study we included 161appar-
ently healthy volunteer men, aged 25-55 
years. Most significant finding was that 
cortisol concentration in hair was posi-
tively correlated with age, body mass 
index, waist circumference, systolic and 
diastolic blood pressure, as well as with 
total and low-density lipoprotein choles-
terol. However, hair cortisol levels were 
not related to the markers of inflammation 
and oxidative stress.
The results of our study suggest that 
chronic stress increases atherosclerosis 
risk through metabolic changes. However, 
the impact of stress on other pathways, 
such as inf lammation and oxidat ive 
stress, has to be address in further more 
detailed studies.
119. Arterial hypertension and 
atherosclerosis: data from Russian 
national registry
Irina Chazova, E. Oshepkova, 
Y. Zernakova, N. Blinova
Russian Cardiology Research and Production 
Complex, Moscow
Objective: Arterial hypertension (AH) is a 
leading cause of morbidity and mortality 
both worldwide and in Russia.
Methods: Data from Russian national 
registry of Arterial Hypertension.
Results: Data from the multicenter obser-
vational study ESSE-RF (Epidemiology of 
Cardiovascular Diseases and their Risk 
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Factors in Regions of Russian Federation) 
showed that the prevalence of AH was 
48,1% in men and 40,7% in women. On 
the other hand according to the Russian 
national registry of Arterial Hypertension, 
which is in place since 2010 and covers 33 
571 patients, the majority of them tends to 
have high and very for CVD events – 38% 
and 56% respectively, 4% - low-risk and 
2% - middle-risk CVD patients. According 
to the registry 32,4% of hypertensive 
patients had coronary heart disease, 19,5% 
had myocardial infarction, 5% - stroke and 
58% - peripheral arterial disease. Preva-
lence of obesity was 38,3% and abdominal 
obesity - 44%.
According to epidemiological ESSE-RF 
study in the total sample 60,6% of partici-
pants had elevated levels of cholesterol 
(> 4,9 mmol/l) and 73,5% of patiens with 
AH, high LDL-C level (>3,0 mmol/l) – in 
58% and in 70,4%, low HDL-C level (<1,0 
mmol/l) – in 18,8% and in 21,6%, hyper-
triglyceridemia (>1,7 mmol/l) – in 24,9% 
and 36,6% respectively.
Conclusions: Data from the epidemiological 
studies and the Russian national registry 
of Arterial Hypertension shows high 
prevalence of dyslipidemia in patients with 
AH, that leads to cardiovascular events, 
such as coronary heart disease, myocardial 
infarction, stroke and peripheral arterial 
disease, therefore to a high and very high 
CVD risk profile.
120. Lifestyle management in 
cardiovascular prevention
Iveta Mintale
Cardiology centre, P.Stradins Clinical university 
hospital, Latvian University
Lifestyle management is a serious tool in 
CV prevention, particularly in high risk 
patients. No smoking, Med diet, regular 
physical activity, which help to maintain 
normal body weight. Easy to say, difficult 
to perform…
In the CV Prevention Guidelines there 
are several pages dedicated to behavioral 
changes – how to facilitate them from 
3 sides: individuals, medical stuff and 
authorities. All of them have high level 
of evidence (IA, IB).
Healthy diet is one of the most impor-
tant tasks. The guidelines say: diet – low in 
saturated fat with a focus on wholegrain 
products, vegetables, fruit and fish. To 
tell this to patient means to say nothing 
– no one knows how to translate this into 
products and meals…
What does it mean – healthy diet in 
real life? First of all high quality products, 
then – optimal size of the plate, and last, 
but not least – high quality fats (prefer-
ably olive oil). This is real life Meditter-
ranean diet which has a huge amount of 
evidence after PREDIMED trial, which 
is easy to follow for a long time, which 
can help to lose weight. High adherence 
to Med diet can significantly reduce the 
risk of MI, stroke and peripheral artery 
disease, diabetes, atrial fibrillation… This 
can reduce a .carotis media thickness and 
even incidence of invasive breast cancer.
Let’s look at one of the CV risk factors 
– obesity! The concept of ‘metabolically 
healthy obesity (the absence of metabolic 
dysfunction), indiv iduals with excess 
adiposity are not at greater cardiovas-
cular r isk, has been controversia l . A 
recent pan-European case-cohort study 
(European Prospective Investigation into 
Cancer and Nutrition study (EPIC-CVD)), 
observed higher cardiovascular risk with 
increasing general and central adiposity. 
It is crucial – to maintain normal body 
weight in order to reduce BP, dyslipidemia 
and risk of developing type 2 DM, and 
thus improve the CV risk profile ( IA). 
Mediterranean diet is the best eating 
style (keeping in mind that low-fat diet 
has no CV benefits), which can reduce CV 
risk even in high risk persons.
It is not easy to change the lifestyle 
in 40ie or 50ies. Definitely education on 
good health should start in the family 
from the early age.
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We should encourage our patients 
to define the meaning of good health 
for themselves to make changes easy to 
rediscover the joy, energy, movement or 
happiness. To be healthy!
121. Goals in blood pressure
Peter M Nilsson
Lund University, Skåne University Hospital, Malmö, 
Sweden
The search for a practical, cost-effective 
and evidence-based blood (BP) goal in 
hypertension is a much debated and hot 
issue over the last few years. Observa-
tional studies have indicated a more or 
less linear relationship between lower 
BP and lower risk, especially for stroke. 
However, some data from randomized, 
controlled studies indicate a J-shaped 
curve for risk of cardiovascular events 
in relation to achieved BP in patients on 
drug treatment for hypertension. The 
European v iew, as manifested in the 
European Society of Hypertension (ESH) 
and European Society of Cardiology (ESC) 
Guidelines on Arterial Hypertension from 
2013 recommend a BP goal below 140/90 
mmHg office BP for most patients, but 
less than 140/85 mmHg in patients with 
diabetes [1]. However, in a recent set of 
recommendations from the American 
Heart Association and related organiza-
tions from November 2017, hypertension is 
defined as a mean BP over 130/80 mmHg 
and BP goals for risk patients should, 
according to these recommendations, be 
below 130/80 mmHg [2]. One argument 
in favor of this more ambitious goal is the 
benefits shown in the SPRINT study in the 
treatment arm randomized to a BP goal 
lower than 120 mmHg, even if adverse 
effects also increased [3]. It should be 
noted that the methodology for meas-
uring BP in SPRINT was unusual, with 
the patient sitting alone in a quiet room 
and using self-monitoring. According to 
critical arguments, this unusual method 
corresponds to BP levels 15 mmHg higher 
based on standard office BP measure-
ments [4].
The debate goes on, but the paradox 
is that so many risk patients still are not 
below the target BP of 140/90 mmHg (a 
“reasonable” goal) while experts debate 
over a “perfect” BP goal. This is an example 
on the importance to focus on subjects at 
high risk before focus is put on subjects 
with relatively low risk. Additional prob-
lems involve compliance with drug intake, 
adverse effects and high costs (for visits, 
not drugs) when lower BP goals are recom-
mended for a great number of the adult 
population. One way for better BP control 
and compliance is to encourage patients 
to use home BP measurements more and 
also trust patients to adjust their own 
antihypertensive drug medication to 
achieve a better control [5]. European 
guidelines will be updated during 2018.
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122. Goals in lipids
Gustavs Latkovskis
Latvian Institute of Cardiology and Regenerative 
Medicine, Riga, Latvia
The recommendations of the European 
guidelines on cardiovascular prevention 
and management of dyslipidemias both 
published in 2016 clearly state that low-
density lipoprotein cholesterol (LDL-C) 
remains the primary l ipid target. In 
contrast to 2013 ACC/AHA guidelines 
which focused more on intensity catego-
ries of statin therapy in context of risk, 
the latest European guidel ines have 
integrated absolute levels and percentage 
reduction as goals of LDL-C management 
in various risk groups. The goals in very 
high- and high-risk groups are defined 
as LDL-C less than 1.8 mmol/ l (and at 
least 50% reduction those with baseline 
levels 1.8-3.5 mmol/ l) and less than 2.6 
mmol/l (and at least 50% reduction those 
with basel ine levels 2.6-5.1 mmol/ l ), 
respectively. The optimal goal in low- to 
moderate-risk patients is less than 3.0 
mmol/ l, but the decision about therapy 
initiation should be individualized and 
carefully balanced and discussed with 
patient. The secondary targets include 
non-high density lipoprotein cholesterol 
(non-HDL-C), apolipoprotein B and total 
cholesterol, but only non-HDL-C optimal 
goals are defined as follows: less than 
2.6 mmol/ l, 3.3 mmol/ l and 3.8 mmol/ l 
in very high-, high- and moderate-risk 
patients, respectively. Triglycerides are 
not a target, but levels above 1.7 mmol/l 
indicate higher risk. Due to recent genetic 
and intervention studies HDL-C cannot 
be regarded as a lipid target anymore. 
It remains to be determined what are 
optimal lipid goals in various risk groups 
and what should be regarded as physi-
ologic normal lipid levels. Studies with 
statins, ezetimibe and PCSK9 inhibitors 
indicate that it is safe to lower LDL-C 
levels to well below 1 mmol/ l, even as 
low as 0.3-0.5 mmol/ l, and there is an 
incremental beneficial effect on athero-
sclerosis non-progression and event 
reduction with such low levels.
123. Goals in glucose
Mart Roosimaa
North Estonia Medical Centre
Both type 1 and type 2 diabetes are known 
cardiovascular r isk factors. Pat ients 
having diabetes are considered to be either 
high or very high cardiovascular risk by 
European Society of Cardiology depending 
on complications and other risk factors. 
Optimal glucose control is one of the key 
targets for reducing these risks. Current 
guidelines suggest glycated haemoglobin 
(HbA1c) of less than 7% as a target for 
most patients, together with fasting 
plasma glucose of 4,4 to 7,2 mmol/L . 
These targets are based on data from 
randomized controlled trials assessing 
dif ferent levels of glycaemic control 
(UKPDS, DCCT, ACCORD, ADVANCE, VADT) 
and their observational follow-up studies. 
In these trials up to 30% reduction in 
cardiovascular events has been observed 
after long-term (25 to 30 years) follow-up 
without the use of GLP-1 receptor agonists, 
DPP-4 and SGLT2 inhibitors. Even though 
there is clear cardiovascular benef it 
from optimal glycaemic control there 
is a marked lag time between adequate 
treatment and risk reduction. Therefore, 
more relaxed glycaemic targets, usually 
HbA1c less than 8 to 8,5%, are suggested by 
guidelines to be appropriate for patients 
with advanced complications, multiple 
comorbidities, recurrent hypoglycaemia, 
limited life expectancy or patients living 
in long term care facilities. While there 
have been no major changes in glycaemic 
targets in over a decade and the choice of 
medications has expanded rapidly, still at 
least one third of patients will not meet 
their targets both in USA and Europe.
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124. History of the Baltic 
Atherosclerosis Society
Margus Viigimaa
North Estonia Medical Centre, Tallinn University of 
Technology, Estonia
The Baltic Atherosclerosis Society was 
founded dur ing the 1st Ba lt ic L ipid 
Conference on the 15th of April, 1998 
in Tal l inn. The mission of the Balt ic 
Atherosclerosis Society is “…advancing 
and exchanging knowledge concerning 
the causes, natural history, treatment 
a nd pre vent ion of  at herosc le rot ic 
disease…” and it could be achieved by 
the “...concerted scientific and clinical 
d iscussions of new developments in 
basic research, diagnosis and therapy of 
atherosclerotic disease”. “Atherosclerosis 
Memorandum” was approved on this 
congress and addressed to all Presidents 
and Prime ministers of three Baltic coun-
tries. The Memorandum has stressed 
very high cardiovascular mortality in 
Estonia, Latvia and Lithuania and has 
demonstrated urgent need to improve 
cardiovascular prevention including 
lifestyle changes and statin treatment.
The f i rst Board members of the 
Society were: Margus Viigimaa (President, 
Estonia), Zita Kučinskienė (President-
elect, Lithuania), Janika Kõrv (Secretary, 
Estonia), Guntis Bahs (Latvia), Andrejs 
Kalvelis (Latvia), Aleksandras Laucevičius 
(Lithuania) and Arvo Mesikepp (Estonia). 
Baltic Atherosclerosis Society has started 
to publish the Baltic Atherosclerosis 
Journal, which has been merged with 
the journal Seminars in Cardiovascular 
Medicine in 2001.
Next congresses of the Baltic Ather-
osclerosis Society were organized as 
follows. The 2nd Baltic Atherosclerosis 
Congress took place in Vilnius, Lithuania 
(2001) the 3rd in Riga, Latvia (2004), the 
4th in Tallinn, Estonia (2007), the 5th in 
Vilnius, Lithuania (2010), the 6th in Riga, 
Latvia (2013). The 7th Congress of the 
Baltic Atherosclerosis Society is taking 
place in Tallinn on April 6-7, 2018.
125. From Biobanking to Precision 
Medicine and beyond: the Estonian 
Experience
Andres Metspalu
The Estonian Genome Center, Institute of Genomics, 
University of Tartu, Estonia
The Estonian Biobank was founded in 
2000 as a population-based biobank. 
18 years later, the biobank includes a 
collection of health and genetics data of 
around 52 000 people and by the end of 
the 2018 it will be increased to 152 000, 
or approximately 15% of the adult popula-
tion. All participants of the biobank have 
donated blood samples for purification 
of DNA and plasma. The whole cohort of 
152 000 will be genotyped with Illumina 
GSA array (currently 52 000). The Human 
Genes Research Act (from year 2000) 
allows regular updating of data through 
linkage to national registries enabling 
long-term follow-up of the cohort and to 
re-contact the gene donors. In the past 
few years increasing amount of attention 
has been placed on translating the results 
of genetic research to improve public 
health. A nationwide technical infrastruc-
ture (X-road) for the secure electronic 
exchange of medical data has also been 
established and is maintained by the state. 
This allows creating the disease (or life!) 
trajectories on all gene donors from the 
birth in the Estonian Biobank, where all 
contacts with the medical systems incl. 
ICD-10 diagnoses, prescriptions, lab data 
and EMR are included. Recently, we have 
completed the deep sequencing of the 
(~30X coverage, PCR-Free) whole genomes 
of 2,500 gene donors and in addition 2500 
whole exomes. Using these data, we have 
demonstrated in the case of familiar 
hypercholesterolemia that “the genetics 
first approach” can discover many new 
FH patients not seen by medical system 
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before and over 50% of cases the treat-
ment was changed. The initial cohort of 52 
000 has been characterized for sequence 
variations (SNV) and imputed using the 
Estonian reference. We are conducting 
several pilot projects in order to work out 
the best ways to return the heath related 
research data -  genetic risks scores (GRS) 
back to people in the biobank who are 
asking for it. For that purpose, we have 
developed the decision support tools for 
several major diseases like CAD, T2D, 
breast cancer etc. During the first contact 
with the genetic counsel and/or medical 
geneticist the rapport will be explained 
and if needed further recommendation 
given. It will be transferred to the medical 
system in next year and together with the 
RITA program on personalized medicine 
in two largest hospital in Estonia the 
personalized medicine as 4P medicine 
(personal, predictive, preventive and 
participatory) has reached to the point 
of no return.
126. Using the principles of 
stratified medicine to individualize 
treatment strategies for diabetic 
patients. 
Experience from the Latvian 
Genome Data Base
Valdis Pīrāgs
Hospital, University of Latvia, Pauls Stradiņš Clinical 
University
The main task of the stratified medicine 
is to identify subgroups of patients with 
particular responses to treatments. The 
Latvian Genome Data Base (LGDB) estab-
lished in 2006 recruits volunteer patients 
from several hospitals as well as healthy 
volunteers. Currently it contains more 
than 33,000 tissue samples and pheno-
type data entries (1,5% of population). 
Our aim is to create a reliable and open 
resource for focused clinical trials in main 
diseases threatening the life expectancy 
and life quality, including cardiovascular 
and cerebrovascular diseases, oncology, 
diabetes and other metabolic diseases as 
well as certain monogenetic pathologies, 
e.g. familial hypercholesterolemia.
In 2008, we started the prospective 
follow–up study OPTIMED as a part of 
the Latvian National Research Program 
“Development of new prevention, treat-
ment, diagnostics means and practices and 
biomedicine technologies for improvement 
of public health” involving 42 endocri-
nologists from health care centers and 
hospitals. The project was primari ly 
focused on drug naïve Type 2 diabetes 
(T2D) patients. One week following the 
drug prescription, the doctors consulted 
their patients via phone in order to collect 
information about possible episodes of 
drug intolerance, the second visit was 
planned after 3 months, all following 
visits - every 6 months.
After we found an association between 
side-effects of metformin and two genetic 
variants of the organic cation transporter 
1 (OCT1), additional recruitment of T2D 
patient with known history of metformin 
use and available HbA1c measurements 
( RetroOPTIMED study) was star ted. 
Altogether more than 600 patients were 
enrolled. Additionally, three novel genetic 
variations in the upstream region of 
organic cation transporter 2 (OCT2) 
and organic cation transporter 3 (OCT3) 
coding genes were shown to be associated 
with short-term efficiency of metformin 
therapy. In cooperation with international 
consortium MetGen a variation in the 
glucose transporter gene SLC2A2 associ-
ated with glycemic response to metformin 
was discovered.
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127. Importance of data quality in 
nation-wide e-health system for 
personalized medicine decision 
support applications
Peeter Ross
Department of Health Technologies, School of 
Information Technologies, Tallinn University of 
Technology, East Tallinn Central Hospital, Estonia
Implementation of Estonian nation-wide 
health information system (EHIS) in 
2008 has paved the way for a develop-
ment of new e-health services during 
the last decade. Besides of traditional 
e -ser v ices l ike d ig ita l prescr ipt ion, 
electronic health record, patient portal, 
etc., also more personalized serv ices 
are emerging – among of others, digital 
decision support systems (DDSS) for 
personalized medicine.
The architecture of EHIS allows secure 
internet-based data exchange between 
several health care data repositories. 
Against this backdrop, different queries 
and decision support algorithms could 
be appl ied across databases. Instead 
of applying DDSS on single electronic 
medical record only, data needed to 
feed algorithms could be retrieved from 
several databases across the country. As an 
example, drug-drug interaction database 
is applied all over Estonia since 2016 to 
find every single potential adverse effect 
while prescribing new drug.
Similar approach could be practiced to 
use DDSS in personalized medicine. DDSS 
in cardiovascular diseases or automatic 
risk score calculators in cancer care could 
be used for advising health care profes-
sionals or patient based on the genome 
data and medical data of the person 
retrieved from different repositories. 
Unfortunately, compared to drug-drug 
interaction database which is using only 
very limited types of data, implementa-
tion of DDSS in personalized medicine is 
much more complex. In later case both 
phenotype and genotype data are used 
which puts very high demands to data 
structuring and quality.
This presentation is to give an over-
view about
1. the importance of ava i labi l it y of 
structured computer readable data 
in electronic medical record,
2. challenges to enter high quality health 
and medical data by health care profes-
sionals,
3. the use of supporting DDSS applica-
tions to increase data quality,
4. secondary use of data in personalized 
medicine, and
5. different types of DDSS in health care.
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201. Genotype-first screening 
and management of familial 
hypercholesterolemia in a 
healthcare-associated biobank
Maris Alver1, 2, Marili Palover1, 2, Aet 
Saar3, 4, Kristi Läll1, 5, Seyedeh Maryam 
Zekavat6, 7, Liis Leitsalu1, Anu Reigo1, Tiit 
Nikopensius1, Tiia Ainla3 ,4, Mart Kals1, 
5, Reedik Mägi1, Stacy Gabriel6, Jaan 
Eha3, Eric Lander6, Alar Irs8, Anthony 
Philippakis6, Toomas Marandi3, 4, Neeme 
Tõnisson1, 9, Pradeep Natarajan6, 10, 11, 
Andres Metspalu1, 2, Sekar Kathiresan6, 10, 
Tõnu Esko1, 6
1 Estonian Genome Center, Institute of Genomics, 
University of Tartu, Tartu, Estonia; 2 Department of 
Biotechnology, Institute of Molecular and Cell Biology, 
University of Tartu, Tartu, Estonia; 3 Department of 
Cardiology, Institute of Clinical Medicine, University 
of Tartu, Tartu, Estonia; 4 Centre of Cardiology, North 
Estonia Medical Centre, Tallinn, Estonia; 5 Institute 
of Mathematics and Statistics, University of Tartu, 
Tartu, Estonia; 6 Broad Institute of Harvard and MIT, 
Cambridge, MA, USA; 7 Yale School of Medicine, 
New Haven, CT, USA; 8 Heart Clinic, Tartu University 
Hospital, Tartu, Estonia; 9 Department of Clinical 
Genetics in Tallinn, Tartu University Hospital, Tartu, 
Estonia; 10 Cardiovascular Research Center and 
Center for Genomic Medicine, Massachusetts General 
Hospital, Boston, USA-10; 11 Department of Medicine, 
Harvard Medical School, MA, USA
Large-scale biobanking efforts with exten-
sive health records and genomic profiles 
provide a powerful platform to identify 
individuals with disease-predisposing 
genetic variants, to faci l itate t imely 
diagnosis and treatment. To explore the 
scope of genomics-guided strategy, we 
applied a genotype-first framework to 
familial hypercholesterolemia (FH), which 
is among the most common single-gene 
disorders and is significantly under-diag-
nosed and inadequately treated. We were 
able to (1) discover 29 individuals with 
FH-associated variants in LDLR, APOB or 
PCSK9 genes based on 30× whole-genome 
(n=2420) or 60× whole-exome sequence 
(n=2384); (2) via cascade screening of 64 
relatives, identify 20 additional carriers; 
(3) via deep-phenotyping, detect overt 
or subclinical atherosclerosis in 57% of 
the variant carriers; and (4) via genetic 
and cardiologic counsel l ing, prov ide 
personalized disease management and 
appropriate therapy initiation or modifi-
cation. No FH-associated variant carriers, 
including those on statins, had achieved 
guidel ine-recommended LDL-C levels 
prior to the study. We reclassified 21 of 
the 42 study participants (50%) from 
having non-specific hypercholesterolemia 
or no diagnosis to having FH, including 
13 (31%) who had not been recognized 
by routine medical care. At the end of 
the study, statin therapy was started or 
uptitrated for 67% of the carriers, and all 
participants were counselled on lifestyle 
modifications. Our systematic analysis 
highlights the power of genomics-guided 
phenotyping as a research tool to facili-
tate preventative clinical care within a 
healthcare-associated biobank.
202. Stockholm-Tartu 
Atherosclerosis Reverse Networks 
Engineering Task (STARNET) - 
A Unique biobank for studying the 
mechanisms of Coronary artery 
disease (CAD)
Raili Ermel, Katyayani Sukhavasi, 
Lars Johan Markus Björkegren, Arno 
Ruusalepp
Tartu University Hospital, Department of Cardiac 
Surgery
The Aim of STARNET study is to enable 
systems genetic studies on layers of 
metabolic and vascularomics data to 
provide insights to the pathogenesis and 
2. POSTER ABSTRACTS
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risk factors of CAD and by that to find 
preclinical biomarkers for early detec-
tion of patients at risk and to find novel 
therapeutic targets of CAD.
Methods: At cardiac surgery department 
in Tartu University Hospital, 1040 CAD 
and 260 control patients going through 
open heart surgery have been enrolled in 
the study. The STARNET database consists 
of extensive phenotypes (including BMI, 
syntax score, laboratory analysis) and the 
biobank of DNA, RNA and proteins from 
multiple tissues (blood, atherosclerosis-
affected and atherosclerosis- free vessel 
walls, metabolic tissues- liver, skeletal 
muscle, omental and subcutaneous fat) 
collected during the perioperative period.
Results:  e STARNET dataset has already 
proven its importance by means of being 
a disease-specifi c database for regaining 
and validating genetic risk loci identifi ed by 
genome-wide association studies (GWAS). 
As an example, inference of gene regulatory 
single nucleotide polymorphisms (eSNPs) 
revealed that the known risk SNPs for LDL 
cholesterol and CAD linked to PCSK9 do 
not regulate PCSK9 expression in liver 
but in visceral abdominal fat emphasising 
the importance of obesity to understand 
risks and etiologies of dyslipidemias and 
premature CAD. However, unlike the case 
with PCSK9 where the associated risk SNP 
had a specifi c role in fat, most CAD risk 
SNPs identifi ed by GWAS were found to 
have multiple Cis and Trans genes acting 
across several tissues whereof some also 
were shared between cardiometabolic 
diseases in regulatory-gene networks.
Conclusions: STARNET is a unique CAD-
specific gene-tissue expression biobank 
with associated phenotypic and deep 
-omics data. Multiple modality disease-
specific datasets like STARNET are needed 
to unravel the molecular networks under-
ly ing complex diseases l ike CAD and 
provide opportunities for novel diagnostic 
markers and therapeutic targets.
203. Endothelial progenitor 
cells, circulating microparticles 
and chemokine receptors in the 
evolution of acute myocardial 
infarction
Carolina França1, 2, Shio MT1, Kato JT2, Costa 
ER2, Izar MCO2, Amaral JB3, Fonseca FAH2
Adjunct Coordinator from Health Sciences Post 
Graduation, São Paulo – SP, Brazil, Santo Amaro 
University
1 Santo Amaro University, Health Sciences Post 
Graduation, São Paulo – SP, Brazil; 2 Federal University 
of São Paulo, Medicine Department, Cardiology 
Division, São Paulo – SP, Brazil; 3 Federal University of 
São Paulo, Otorhinolaryngology Department – Head 
and Neck Surgery, São Paulo – SP, Brazil
Objective: To compare two lipid-lowering 
strategies after acute miocardial infarc-
tion (AMI), concerning endothelial progen-
itor cells, circulating microparticles and 
monocyte chemokine receptors.
Methods: This is a PROBE (prospective, 
randomized, open label trial with blinded 
endpoints) study (ClinicalTrials.gov Identi-
fier: NCT02428374). Adult patients (n=129) 
of both genders, ageing 18-75 years, were 
randomized in a 2x2 factorial design for 
treatment with rosuvastatin 20 mg/day 
or simvastatin 40 mg/day plus ezetimibe 
10 mg/day as well as ticagrelor 90 mg 
2x/day and clopidogrel 75 mg, in addi-
tion to conventional AMI therapy. Blood 
samples were collected at baseline, after 
one month and six months of treatment. 
Endothelial progenitor cells (CD34+/KDR+/
CD133+) and circulating microparticles 
(from endothelial cells CD51+/CD105+, 
platelets CD42+/CD31+ and monocytes 
CD14+) were identified and characterized 
by f low cytometry. Monocyte chemokine 
receptors (CCR2, CCR5 and CX3CR1) were 
analyzed by real time PCR. Results: When 
compared during the six months of treat-
ment, there were no diferences, between 
the four groups, in the percentage of 
endothelial progenitor cells, as well as for 
the number of circulating microparticles 
for the three subpopulations evaluated 
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(endothel ia l , platelet and monocy tic 
microparticles) (p=ns, Kruskall-Wallis 
Test). However, considering the time 
of treatment (baseline x one month x 
six months), there were differences for 
endothelial and monocytic microparti-
cles (p=0.033 and p=0.002 respectively, 
Friedman Test). The preliminary results 
related to chemokine receptors suggested 
an increase around 10 times in the expres-
sion of CCR2 and CX3CR1 after one month, 
followed by a reduction at six months of 
treatment, without differences for CCR5.
Conclusion: Our data suggest a t ime-
dependent modulation of endothelial and 
monocytic microparticle levels, CCR2 and 
CX3CR1 expressions, without differences 
for platelet microparticles and endothelial 
progenitor cells. These changes do not 
seem to be affected by the choice of the 
lipid-lowering strategy.
204. A Comparison of Decision 
Tree Induction with Binary Logistic 
Regression for the Prediction of 
the Risk of Cardiovascular Diseases
Ingrida Grabauskytė1, Abdonas 
Tamošiūnas1, Mindaugas Kavaliauskas2, 
Ričardas Radišauskas1, Gailutė 
Bernotienė1, Vytautas Janilionis1
Department of Population Studies, Institute of 
Cardiology Lithuanian University of Health Sciences
1 Institute of Cardiology, Medical Academy, 
Lithuanian University of Health Sciences, Lithuania; 
2 Faculty of Mathematics and Natural Sciences, 
Kaunas University of Technology, Lithuania
Abstract:  e main purpose of this presen-
tation was to compare traditional binary 
logistic regression analysis with decision 
tree analysis for the evaluation of the risk of 
cardiovascular diseases in adult urban men.
Subjects and methods: In our study, we 
used data from the Multifactorial Ischemic 
Heart Disease Prevention Study (MIHDPS). 
In the MIHDPS study, a random sample of 
male inhabitants of Kaunas city (Lithu-
ania) aged 40–59 years was examined 
between 1977 and 1980. We analysed a 
sample of 5,626 men.
Results: Taking blood pressure lowering 
medicine, disability, intermittent claudica-
tion, regular smoking, a higher value of the 
body mass index, systolic blood pressure, 
age, total serum cholesterol, and walking in 
winter were associated with a higher prob-
ability of ishemic heart disease or cardio-
vascular diseases. Having more siblings 
and drinking alcohol were associated with 
a lower probability of these diseases.
Conclusions:  e binary logistic regression 
method showed a very slightly lower level 
of errors than the decision tree did (the 
diff erence between the two methods was 
0.1338 % for ishemic heart disease (IHD) and 
0.1029% for cardiovascular disease (CVD), 
but for consumers, the decision tree is easier 
to understand and interpret the results. 
Both of these mehods are appropriate to 
analyze cardiovascular disease data.
205. Familial hypercholesterolemia 
management tool in the North 
Estonia Medical Centre
Silver Heinsar, Margus Viigimaa,
North Estonia Medical Centre, Tallinn University of 
Technology, Estonia
Objectives: Familial hypercholesterolemia 
(FH) is underdiagnosed and undertreated 
in the general population. Our objective was 
to create a clinical tool which could improve 
correct diagnosis of FH, assemble FH patients 
into a clinical database and give further 
instructions about the best treatment 
approach according to individual patients 
Dutch Lipid Clinic Network Score (DLCNS).
Methods: An algorithm was introduced 
to North Estonia Centre of Medicine's IT 
system which made DLCNS mandatory 
if patients had LDL-cholesterol levels ≥5 
mmol/L and they had been diagnosed 
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with pure hypercholesterolemia (classifi ed 
under E78.0 in ICD-10).  e tool provides 
clinicians with a comfortable way to fi ll 
the score with explanations about each 
criteria and automatically groups patients 
into fi ve subgroups in the clinical data-
base according to the likeliness of FH 
diagnosis. Furthermore, the clinician gets 
clear instructions about the next steps of 
treatment based on individual score points.
Results: The tool launched in active use 
starting from 01.01.2018 and not only 
has it assembled first patients into the 
database, but also led to numerous physi-
cians, nurses and other medical personnel 
seeking advice on other aspects of diag-
nosis and care in patients with familial 
hypercholesterolemia. The long term 
objective of this project is to spread the 
tool throughout other major hospitals of 
Estonia in order to enhance the correct 
diagnosis and treatment in Estonian 
population and prevent early morbidity 
and mortality in this highly susceptible 
and undertreated disease population.
206. Common polymorphisms are 
unlikely to play a major role in 
pseudo - FH development in Czech 
population
Hubacek J.A.1, Dlouha D.1, Tichy L.2, 
Fajkusova L.2, Freiberger T.3
1 Center for Experimental Medicine, IKEM, Prague, 
Czech Republic; 2 Centre of Molecular Biology and 
Gene Therapy, University Hospital Brno, Czech 
Republic; 3 Molecular Genetics Laboratory, Centre 
for Cardiovascular Surgery and Transplantation, 
Brno, Czech Republic
Objective: Familial hypercholesterolemia 
(FH) is a serious disease, leading (if not 
treated) to premature myocardial infarc-
t ion. FH is caused predominantly by 
mutations within the LDL receptor and 
APOB genes. Recently, gene scores have 
been defi ned, suggesting the existence of 
“pseudo - FH”, clinically indistinguishable 
from classical FH, but without one causal 
mutation. In our study, we have analyzed 
17 LDL-cholesterol associated (in general 
population) SNPs in Czech patients with FH.
Methods: Polymorphisms within PCSK9, 
NYNRIN, ST3G, SORT1 (two SNPs), ABCG8, 
LDLR, APOB (two SNPs), SLC22, PPP1R3, 
MYLIP, HFE, CETP, CILP/PBX4, BRAP and 
HMGCoAR were genotyped using Taqmann 
technology on an AB 7300 RT PCR cycler 
or using PCR-RFLP in 298 FH patients 
without the causal mutation and in 296 
patients with the LDL receptor mutation.
Results: Frequencies of the individual 
genotypes signifi cantly diff er between two 
analyzed groups only in the case of CILP/
PBX4 – rs1699148 (P < 0.005) and APOB 
– rs1367117 (P < 0.005) genes. Genotype 
frequencies of other polymorphisms did 
not diff er between the analysed groups.
Conclusion:  e results from our study 
suggest that common genetic variants will 
not play a major role in the “pseudo-FH” 
development in Czech population. Only two 
of seventeen analysed SNPs seem to be of 
clinical importance and to infl uence the 
development of the pseudo - FH phenotype.
Supported by Ministry of Health of the Czech Republic, grant 
nr. 15-28277A. All rights reserved.
207. Pigment epithelium derived 
factor in patients with type 2 
diabetes: its relationship to 
endothelial hemostatic markers
David Karásek1, Jaromíra Gajdová1, 
Veronika Kubíčková2, Ondřej Krystyník1, 
Lubica Cibičková1, Helena Vaverková1
1 Third Department of Internal Medicine – 
Nephrology, Rheumatology and Endocrinology, 
Faculty of Medicine and Dentistry, University 
Hospital and Palacky University, Czech Republic; 
2 Department of Clinical Biochemistry, University 
Hospital, Czech Republic
Introduction: Pigment epithelium derived 
factor (PEDF) belongs to relatively novel 
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adipokines, which may participate in 
insulin resistance and vascular damage. 
Aim of the study was to compare PEDF 
circulat ing levels in type 2 diabetes 
patients with and without metabolic 
syndrome (MS) to healthy controls and 
assess PEDF relations to risk cardiovas-
cular factors and endothelial hemostatic 
markers.
Methods: Fifty individuals with type 2 
diabetes (23 men, 27 women) and forty 
healthy controls (15 men, 25 women) were 
included to this pilot study. PEDF, anthro-
pometric parameters, markers of insulin 
resistance and diabetes compensation 
were investigated in all subjects. Diabetics 
were divided into two groups: with (n=30; 
11 men, 19 women) and without (n=20; 12 
men, 8 women) MS. Von Willebrand factor 
(vWF), tissue plasminogen activator (t-PA) 
and plasminogen activator inhibitor-1 
(PAI-1) served as markers of endothelial 
dysfunction.
Results: Compared to healthy controls 
only diabetics with MS had higher levels 
of PEDF [14160 (10240-16000) ng/ml versus 
11120 (8560-14400) ng/ml; p<0.05]. In 
all subjects PEDF significantly (p<0.05) 
correlated: positively with BMI, waist 
circumference, hs-CRP, triglycerides, 
non-HDL cholesterol, apolipoprotein B, 
fasting glucose, glycated hemoglobin, 
C-peptide and insulin; negatively with 
HDL-cholesterol and apolipoprotein A1. 
Additionally, in diabetics with MS a nega-
tive correlation of PEDF with vWF ( =-0.46 
p < 0.05) were found.
Conclusion: Patients with type 2 diabetes 
and MS have significantly higher levels of 
PEDF, which are associated with symptoms 
of MS and insulin resistance. A negative 
correlation of PEDF with vWF may point 
out its vascular protective role.
Supported by IGA_LF_2017_015, IGA_LF_2018_010 and MH 
CZ DRO (FNOl, 00098892)
208. PCSK9 Inhibitor Causes 
a Reduction in the Level of 
Oxidatively Modified Low-Density 
Lipoproteines in Patients with 
Atherosclerosis
Vadim Lankin, Alla Tikhaze, Irina 
Chazova, Margus Viigimaa
Russian Cardiology Research Center, Moscow; Tallinn 
University of Technology, Estonia
Objective: The effect of the cholesterol-
lowering drug - inhibitor of protein 
conver tase subt i l i s in/ kex in t y pe 9 
(PCSK9) evolocumab of Amgen company 
(in a dose of 420 mg once a month) on the 
level of oxidatively modified LDL (ox-LDL) 
and the activity of antioxidant enzymes 
in the blood of patients with coronary 
atherosclerosis was investigated.
Methods: The level of oxidatively modi-
f ied LDL (ox-LDL) was determined by 
the immunochemical method using the 
Mercodia Oxidized LDL ELISA test kits 
(Sweden).
Results: In our study the PCSK9 inhibitor 
reduced the LDL cholesterol level in 
patients with coronary atherosclerosis 
by more than 80% for 3 months. The 
level of ox-LDL progressively decreased 
after the administration of PCSK9 and 
remained at a reduced level (more than 
2-fold) within 12 months after initiation 
of therapy. Revealed a strong positive 
correlation (r = 0,79; p <0.01) between 
the ox-LDL and LDL cholesterol levels. The 
activity of key antioxidant enzymes (SOD, 
GSH-peroxidase, catalase) in erythrocytes 
of patients with PCSK9 therapy did not 
significantly change over the whole period 
(12 months) of observation.
Conclusions: Thus, unlike statins, the 
cholesterol-lowering drug - inhibitor 
PCSK9 does not cause a decrease in the 
level of natural antioxidants and contrib-
Eesti Arst 2018;97(Lisa1):1–48 39
7TH BALTIC ATHEROSCLEROSIS SOCIET Y CONGRESS
utes to a decrease in the level of athero-
genic oxidatively modified LDL.
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209. Plasma kynurenine pathway 
metabolites are associated 
with mortality in patients with 
predominantly ischemic heart 
failure
Anders Lund1, Jan Erik Nordrehaug1, 2, 
Grete Slettom3, Øivind Midttun4, Arve 
Ulvik4, Per Magne Ueland1, 5, Ottar 
Nygård1, 3, Lasse Melvaer Giil1,6
1 Department of Clinical Science, University of 
Bergen, Bergen, Norway, 2 Department of Cardiology, 
Stavanger University Hospital, Stavanger, Norway, 3 
Department of Heart Disease, Haukeland University 
Hospital, Bergen, Norway, 4 Bevital AS, Bergen, 
Norway, 5 Laboratory of Clinical Biochemistry, 
Haukeland University Hospital, Bergen, Norway, 
6 Department of Internal Medicine, Haraldsplass 
Deaconess Hospital, Bergen, Norway
Objective: Circulating concentrations of 
metabolites of tryptophan produced via 
the kynurenine pathway (kynurenines), are 
linked to all-cause mortality in coronary 
artery disease, but have not been exten-
sively explored in patients with clinical 
heart failure. We aimed to compare plasma 
levels of kynurenines between patients 
with predominantly ischemic heart failure 
and controls, and to investigate whether 
kynurenines predict mortality.
Methods and results:  e study included 
202 patients with heart failure and 264 
controls without heart disease (propen-
sity score matched by age and gender). 
A l l participants underwent coronary 
angiography and cine ventriculography. 
Plasma kynurenines, pyridoxal 5’phos-
phate (PLP), C-reactive protein (CRP) and 
monocyte count were measured at baseline. 
Case-control diff erences were assessed by 
logistic regression and mortality-hazard 
by Cox regression. Results were adjusted 
for multiple testing. Ninety-four (47%) 
of the heart failure patients died during 
the follow-up period. Kynurenine (Kyn, 
[OR 1.65, p < 0.001]) and the kynurenine-
tryptophan-ratio (KTR, [OR 1.63, p < 0.001]) 
were higher in patients with heart failure 
than in controls. KTR [HR 1.59, p = 0.006], 
3-hydroxykynurenine (HK, [HR 1.65, p < 
0.001]), and the ratio of HK to xanthurenic 
acid (HK/XA, [HR 1.67, p < 0.001]) were 
all associated with increased mortality.
Conclusion: Metabolites of the kynurenine 
pathway, related to innate immune activa-
tion and apoptosis, are increased in heart 
failure and associated with mortality. 
Whether these associations reflect mainly 
underly ing causes that ac t ivate the 
pathway or effects of the kynurenines 
themselves remains undecided.
210. Comparison of atherosclerotic 
lesions in brachiocephalic and 
coronary arteries in famial 
hypercholesterolemia patients
Georgijs Ņesterovics, Vita Saripo1, 2, 3, 
Arta Upena-Roze3, Dainus Gilis3, Andrejs 
Erglis1, 2, 3, Gustavs Latkovskis1, 2, 3
Faculty of Medicine, University of Latvia
1 Faculty of Medicine, University of Latvia, Riga, 
Latvia; 2 Latvian Institute of Cardiology and 
Regenerative Medicine, University of Latvia, Riga, 
Latvia; 3 Pauls Stradins Clinical University Hospital, 
Latvian Center of Cardiology, Riga, Latvia
Objective: Early diagnosis of atheroscle-
rosis in brachiocephalic arteries helps to 
identify very-high risk individuals among 
patients with familial hypercholester-
olemia (FH). We explored how well does 
presence or absence of atherosclerosis in 
brachiocephalic arteries correspond to 
lesions in coronary arteries in FH patients.
Methods: Among 175 FH patients diag-
nosed at the Latvian Registry of FH, we 
selected patients who had undergone 
both coronary imaging (MS-CT or invasive 
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coronary angiography) and ultrasound of 
brachiocephalic arteries.
Results:  e data on both coronary and 
brachiocephalic arteries were available 
for 64 patients (Table). Mean age (SD) was 
53.7+13.4 years, and 20 (31.3%) were men. 
Among 16 (25%) patients with no evidence 
of brachiocephalic atherosclerosis, 10 
(63%) had coronary atherosclerosis and 
4 of them (25%) had a coronary stenosis 
>50%. Among 12 patients with no coronary 
lesions 6 (50%) had evidence of brachioce-
phalic disease. Only 6 (9.4% of all) patients 
had no atherosclerosis in both locations. 
Correlation between lesions and their 
severity in coronary and brachiocephalic 
arteries was signif icant (Spearman’s 
rho=0.337, p=0.007).
Conclusions: The correlation between 
brachiocephalic and coronary atheroscle-
rosis is low in patients with FH. Evidence 
of coronary atherosclerosis is found in 
majority of FH patients with normal 
brachiocephalic ultrasound f indings. 
Absence of brachiocephalic atherosclerosis 
is not a reliable method to exclude very 
high risk in FH patients.
211. Targeted lipidomics of arterial 
stiffness and hemodynamics in 
atherosclerosis
Kaido Paapstel, Jaak Kals2, 3, 4,Jaan Eha1, 2, 
Kaspar Tootsi2, Aigar Ottas3, Anneli Piir3, 
Mihkel Zilmer2,3
Department of Cardiology, University of Tartu
1 Department of Cardiology, University of Tartu; 
2 Endothelial Centre, University of Tartu; 3 Institute of 
Biomedicine and Translational Medicine, Department 
of Biochemistry, Centre of Excellence for Genomics 
and Translational Medicine, University of Tartu; 
4 Department of Surgery, University of Tartu
Objective: Metabolomics approach provides 
a detailed insight into lipid metabolism and 
allows to study the levels and roles of its 
numerous intermediates and products in 
the pathogenesis of cardiovascular disease 
(CVD). Our study aimed to investigate the 
relationship between the lipidomic profi le, 
arterial function and hemodynamics in 
coronary artery disease (CAD) patients, 
peripheral arterial disease (PAD) patients 
and healthy controls.
Methods: We studied 52 patients with 
CAD, 32 patients with PAD, and 40 appar-
ently healthy controls. All of them were 
male. Serum levels of 40 acylcarnitines, 
76 phosphatidylchol ines (PC) and 14 
lysophosphatidylcholines ( lysoPC) were 
determined with the AbsoluteIDQ™ p180 
kit (BIOCRATES). Arterial applanation 
tonometry (Sphygmocor, Atcor Medical) 
was used for pulse wave analysis and 
Table. Findings in brachiocephalic and coronary arteries (n=64).
Brachiocephalic arteries
Atherosclerosis in coronary arteries
Stenosis 
> 50%
Stenosis 
10-50% Plaque
No athero-
sclerotic 
lesions
Total (100%)
Stenosis > 50% 6 (60%) 1 (10%) 2 (20%) 1 (10%) 10
Stenosis 10-50% 15 (62%) 4 (17%) 3 (13%) 2 (8%) 24
Plaque 4 (29%) 5 (36%) 2 (14%) 3 (21%) 14
No atherosclerotic lesions 4 (25%) 3 (19%) 3 (19%) 6 (37%) 16
Total 29 (45%) 13 (20%) 10 (16%) 12 (19%) 64
INNOVATSIOON FOOKUSES
AstraZeneca Eesti OÜ, Järvevana tee 9, Tallinn 11314
Astma 
Krooniline 
obstruktiivne 
kopsuhaigus
Rinnavähk 
Kopsuvähk
Munasarjavähk
Hematoloogilised kasvajad
Koronaarhaigus
Krooniline neeruhaigus
Diabeet
EE-0398-02-18-ONC-DIA-RIA-CV
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carot id-femora l pu lse wave veloc it y 
(cf-PWV) assessments.
Results: 1) Acylcarnitine profile (CAD 
patients vs healthy subjects): elevated 
levels of C16:1, C18:1, C3-DC(C4-OH), PC 
aa C40:6, Met-SO/Met were observed in 
the CAD group compared to the healthy 
controls. The cf-PWV showed positive 
correlations with C14, C16:1, (C2 + C3) 
/ C0, C2 / C0 and the CPT-1 ratio for 
the CAD group. Moreover, PCA-derived 
factor 3 (acylcarnitines) proved to be an 
independent determinant of cf-PWV for 
these patients. 2) PC and lysoPC profi les 
(CAD patients vs PAD patients vs healthy 
subjects): decreased serum levels of several 
PC and lysoPC species (e.g., PC aa C28:1, PC 
aa C30:0, PC aa C32:2, PC ae C30:0 and PC 
ae C34:2, lysoPC a C18:2) were observed for 
both patient groups in comparison to the 
healthy controls. Further, a considerable 
number of PCs and lysoPCs were inversely 
related to either cf-PWV, heart rate, asym-
metric dimethylarginine (ADMA) or ADMA/
arginine only for patients.
Conclusions: In addition to the classical 
lipid-related CVD risk markers, the inter-
mediates of lipid metabolism may serve 
as novel indicators for altered vascular 
function and hemodynamics.
212. Severe hypertriglyceridemia: 
clinical and laboratory 
characteristics
Martin Šatný, Jan Dobiáš1, Martina 
Vaclová1, Lukáš Zlatohlávek1, Tomáš 
Štulc1, Pavel Horák1, Barbora Grauová1, 
Michaela Šnejdrlová1, Richard Češka1, 
Michal Vrablík1
13rd Internal Department, First Faculty of Medicine 
Charles University and General Teaching Hospital in 
Prague, Czech Republic
Objective: Severe hypertriglyceridemia 
(SH) is def ined as plasma concentra-
tion of triglycerides above 10mmol/ l, 
which is determined by polygenic type 
of inheritance in the presence of addi-
tional triggers (insulin resistance, type 
2 diabetes, alcohol abuse). It is associated 
with the risk of acute pancreatitis, while 
the risk of cardiovascular complications 
is not significantly elevated. The aim of 
this study is to characterize clinical and 
laboratory findings in patients with SH.
Methods. A cohort of unrelated patients 
with at SH was selected from our patient 
database. In total, 58 women and 187 men 
were identified, with an average age of 
57.0±11.6years. Biochemical parameters 
were determined enzymatically using an 
automated analyzer.
Results: The median of highest TG was 
18.3±25.11mmol/l, TC 9.89±6.32mmol/l, 
respectively. The latest measured values 
in the majority of patients treated with 
a statin and fenofibrate had median TG 
3.19±6.78mmol/l and TC 5.05±2.27mmol/l. 
15% of women and 19.8% of men had 
at least one attack of acute pancrea-
titis in their medical histories. Median 
BMI was 29.0±4.7kg/m2 and glycemia 
6.0±4.4mmol/ l . Type 2 d iabetes was 
diagnosed in 44.9% men and 57% women.
Conclusion: Manifestation of SH is trig-
gered by a number of factors (insulin 
resistance, type 2 diabetes and obesity) 
as documented by their high prevalence 
in our cohort of patients. A history of 
acute pancreatitis was identified in 15% 
women and 19.8% men. This subgroup did 
not differ in serum lipid concentrations 
from the group without this history. 
Identification of other factors leading to 
acute pancreatitis in the context of SH 
requires further research.
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213. Comparison of two-year 
clinical outcomes after implantation 
of fi rst and second generation 
drug-eluting stents in left main 
coronary artery stenosis in patients 
with hypercholesterolemia: real-life 
registry sub-analysis
Emma Sokolova, Briede I.,Narbute I., 
Sondore D., Kumsars I., Dombrovskis A., 
Latkovskis G., Trusinskis K., Jegere S., 
Lismanis A., Dombrovska K., Rudzitis A., 
Strenge K., Grave A., Apalva K, Erglis A.
Pauls Stradins Clinical University Hospital, Riga, 
Latvia, University of Latvia, Riga, Latvia
Objectives: Eva luate 2-year c l in ica l 
outcomes of unprotected left main (LM) 
coronary artery percutaneous coronary 
intervention (PCI) in patients with hyper-
cholesterolemia. We compare results 
in two patient groups who receive fi rst 
(Delta1) and second (Delta2) generation 
drug eluting stents (DES).
Methods: Between October 2002 and June 
2011 from two databases of unprotected 
LM PCI (n=895) we selected 689 (n=78.0%) 
patients with hypercholesterolemia, 
analyzed clinical, angiographic results: 
al l-cause death, cardiac death, target 
vessel-related myocardial infarction (MI), 
target lesion revascularization (TLR), 
target vessel revascularization (TVR), 
scaffold thrombosis (ST), cerebrovascular 
events (CVE).
Results: Man population 69.5 % (n=485), 
mean age 65.97 ± 10.16 years. Active 
smoking 15.3% (n=113), diabetes mellitus 
15.3% (n=107), previous CABG 1.6% (n=11), 
prev ious PCI 47.7% (n=333). Cl in ica l 
follow-up reached 80.8% (n=564) patients. 
Mean stent length 19.40 ± 7.56 mm. LM 
ostial PCI 10.5% (n=73), body PCI 13.5% 
(n=94), distal PCI 66.2% (n=462). All cause 
death 2.6% (n=2) observed in Delta1, 2.1% 
(n=10) in Delta2 (p=0.776). The overall 
rate of all reason death was 7.7% (n=6) 
in Delta1 group vs Delta2 (n=4) (7.7% vs. 
0.8%; p<0.001). TLR was observed in 5.1% 
(n=4) in Delta1 vs 2.7% (n=13) in Delta2 
(p=0.0236). TVR 11.5% (n=9) in Delta 
1 vs 7.2% (n=35) in Delta2 (p=0.18). MI 
was 7.7% (n=6) vs 0.8% in Delta2 (n=4); 
(p<0.001). CVE was observed 2.6% (n=2) in 
Delta 1 vs 0.4% (n=2) in Delta2 (p=0.04). 
Definite stent thrombosis1.5% (n=1) only 
in Delta1. CABG, cerebrovascular events 
did not differ significantly.
Conclusions: Second generat ion DES 
showed stat ist ica l ly better two-year 
results in patients with hypercholester-
olemia and LM PCI in terms of all reason 
death, MI and stent thrombosis.
214. Comparison of two-
year clinical outcomes after 
implantation of first and second 
generation drug-eluting stents in 
left main coronary artery stenosis 
in patients with diabetes mellitus: 
real-life registry sub-analysis of 
the Latvian Centre of Cardiology
Kristine Spalva, Briede I., Narbute I., 
Sondore D., Kumsars I., Dombrovskis A., 
Latkovskis G., Trusinskis K., Jegere S., 
Lismanis A., Dombrovska K., Rudzitis A., 
Strenge K., Grave A., Sokolova E., Erglis 
A. Pauls
Stradins Clinical University Hospital, Riga, Latvia, 
University of Latvia, Riga, Latvia, Rīga Stradiņš 
University, Riga, Latvia
Objective: We evaluated 2-year clinical 
outcomes of unprotected left main (LM) 
coronar y ar ter y percutaneous coro-
nary intervention (PCI) in patients with 
diabetes mellitus. We compare results 
in two patient groups with diabetes 
mellitus who receive first (Delta1) and 
second (Delta2) generation drug eluting 
stents (DES).
Methods: Between October 2002 and June 
2011 there were two databases registry 
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of unprotected left main PCI (n=895) 
collected at the Latvian Center of Cardi-
ology registry, a high-volume PCI center. 
From these two databases, we selected 136 
(15.2%) patients with diabetes mellitus for 
follow-up analysis. In Delta1 (n=174) and 
Delta2 groups (n=712), 22 patients (12.6%) 
and 114 patients (16.1%) were diabetics, 
respectively. Both branch stenting was 
performed 15 patients (11.0%). Elective 
PCI were 117 (86.0%). During follow-up, 
we analyzed clinical and angiographic 
results such as all-cause death, cardiac 
death, target vessel-related myocardial 
infarction (MI), target lesion revasculari-
zation (TLR), target vessel revasculari-
zation (TVR), scaffold thrombosis (ST), 
cerebrovascular events (CVE).
Results: Clinical follow-up reached 106 
(77.9%) patients. One in-hospital death 
was observed in patient from Delta1 
group. Hospital MI were detected in 3 
(2.2%) patients, mostly in Delta1 group 
as compared with Delta2 (2 (9.1%) vs. 1 
(0.9%); p=0.017). There was no in-hospital 
TLR, TVR, CVE. The overall rate of all 
reason death in follow up period were 
3 (2.8%), more frequent in Delta1 group 
as compared with Delta2 (2 (9.1%) vs. 
1 (1.2%); p=0.047). MI were observed 
4 (3.8%) patients, frequently in Delta1 
group as compared with Delta2 (3 (13.6%) 
vs. 1 (1.2%); p=0.008). TLR and TVR did 
not show significant difference between 
these groups. Definite ST were detected 
in 2 (1.9%) patients from Delta1 group.
Conclusions: Second generat ion DES 
showed stat ist ica l ly better two-year 
results in patients with diabetes mellitus 
and LM PCI in terms of all reason death, 
MI and stent thrombosis.
215. Stockholm-Tartu 
Atherosclerosis Reverse Networks 
Engineering Task (STARNET)- 
A Systems Genetic Study of 
Atherosclerotic Cardiovascular 
Disease
Katyayani Sukhavasi, Raili Ermel, 
Lars Johan Markus Björkegren, Arno 
Ruusalepp, Heli Järve
Tartu University, Department of Pathophysiology
Introduction: Atherosclerotic cardiovas-
cular disease is not a single locus disease, 
but a systemic and progressive disease. 
In 2015, the global death from athero-
sclerotic cardiovascular disease was 17.7 
million , out of which 6.7 million were 
due to stroke. A better understanding at 
molecular and cellular levels is needed 
and can be achieved by using Systems 
Genetics; applying advanced algorithms 
on omics data sets to disclose networks 
driving molecular process in diseases.
Aim: The STARNET study was started 
initially to study patients with coronary 
artery disease,but to extend the under-
standing of atherosclerosis systematically 
we have also included patients with severe 
carotid stenosis, which is another athero-
sclerotic cardiovascular disease with out 
good preclinical markers frequently diag-
nosed only after a clinical event.
Methods: 220 patients who underwent 
carotid endarterectomy due to severe 
carotid stenosis have been enrolled at the 
Department of Vascular surgery, Tartu 
University Hospital. Phenotypic data along 
with a biobank of DNA, RNA from multiple 
tissues (blood, metabolic tissues- skeletal 
muscle, subcutaneous fat, atherosclerotic 
carotid plaque) is collected during the 
peri-operative period. The atherosclerotic 
plaque is also stored in OCT media for 
immuno-histologic analysis. The central 
cellular pathway of atherosclerosis being 
the monocyte-macrophage-foam cell is 
also studied. Single cell RNA sequencing 
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by FACS sorting of plaques will help to 
refine the data analysis at the level of 
individual plaque cells.
Conclusion: Characterization of cell popu-
lat ions in Carotid plaque along with 
clinical correlations and deep omics data 
will be an important resource to better 
understand the molecular underpining 
of carotid stenosis and as such pave the 
way for novel therapeutic targets and to 
early diagnose patients at risk for stroke.
216. First Time Study On Quality Of 
Life In Obese Children In Estonia
Lagle Suurorg1, Margit Juudas1, Juta 
Lusti1, Inna Kramer2
Tallinn Children’s Hospital, Tallinn Children’s Hospital 
Foundation, Position: LS1 Head of Department for 
Quality Assurance;MJ1 and JL1 physiotherapists; IK2 - 
Tallinn Children’s Hospital Foundation (CEO)
Objective: To assesse health-related quality 
of life (HRQOL) in schoolage obese chil-
dren who participated in the Clinical-
Community Childhood Obesity Interven-
tion project „Personalized approach in 
child obesity management“, implemented 
in partnership with children’s hospital 
and Foundation.
Methods: The Pediatric Quality of Life 
Inventory (PedsQoL™ 4.0 SF15, Varni, 
Seid&Rode,1999) is a generic HRQOL 
questionnaire consisting of 23 items rated 
on a 5-point Likert Scale with 4 domains: 
physical , emotional, social and school 
functioning. Scales are standardized with 
scores ranging from 0 to 100, with higher 
scores indicating better quality of life. 
Special tool in assessment of children’s 
lifestyle, child’s and  parent’ motivation 
by VAS (1-10) and selection of real goals to 
improve lifestyle was used. Demographic 
information included age, sex, and anthro-
pometric data, body mass index (BMI) 
percentiles by CDC norms adjusted for 
age and sex (CDC,2000).
Participants: 25 obese children (BMI ≥ 95 
percentile) and their parents completed 
separately PedsQoL™ inventory in physi-
cian’s off ice. Statistical analysis were 
conducted using SPSS for Windows.
Results: Mean age of children was 12±2 
years, among them 63% boys and 37% girls. 
General PedsQoL total score in children 
was 16 % lower and parent proxy report 
score was 44% lower than in healthy chil-
dren. Largest diff erence comparing with 
healthy children was found in children 
self –reported and parents’ proxy reported 
emotional functioning. Item-scale corre-
lation demonstrated that most items for 
child self-report and all items for parents’ 
proxy report exceeded the minimal reli-
ability standard of 0,7.
Conclusion: The f irst examination of 
quality of life on all aspects of obese child 
functioning using standardized ques-
tionnaires showed agreement between 
mean pediatric and mean parents’ proxy-
reported scores. We proposed that studies 
of targeted interventions to treat obesity 
in children should include an assessment 
of HRQOL.
217. Chronic and oxidative stress 
association with total count 
of endothelial microvesicles in 
healthy young male plasma
Vytautas Žėkas1,2, Reda Matuzevičienė1, 
2, Dovilė Karčiauskaitė1, 2, Asta 
Mažeikienė1, Neringa Burokienė1, Mantas 
Radzevičius1, 2, Aušra Janilionienė2, Aušra 
Linkevičiūtė1, 2, Zita Kučinskienė1, 2
Faculty of Medicine, Biomedicine institute, Vilnius 
University, Lithuania.
1 Departament of Physiology, Biochemistry, 
Microbiology and Laboratory Medicine, Biomedicine 
institute, Faculty of Medicine, Vilnius University, 
Lithuania; 2 Center for laboratory medicine, Vilnius 
University hospital Santaros Clinics, Vilnius
Objectives: The objective of this study 
was to test the correlat ion between 
Eesti Arst 2018;97(Lisa1):1–48 47
7TH BALTIC ATHEROSCLEROSIS SOCIET Y CONGRESS
oxidative and chronic stress markers 
and and endothelial microvesicle count 
in peripheral blood.
Methods: Study included 81 males who 
were aged between 25 and 55 years and 
apparently healthy. Venous blood samples 
were label led w ith ant i-CD144-FITC, 
ant i-CD105-BV421, ant i-CD42a-PerCP, 
anti-CD62e-PE, anti-CD31-APCy7 and anti-
CD61-APC (BD, San Jose) and tested using 
a BD LSR Fortessa cytometer (BD, San 
Jose). Events were gated on forward and 
side-scattered light parameters. Malon-
dialdehyde and cortisol concentrations 
were measured using high performance 
liquid chromatography.
Results: Four populations of endothelial 
microvesicles expressing combination of 
CD105+, CD31+, CD144+, CD62e with CD42a- 
or CD42a+ markers were examined. We 
found correlations between malondialde-
hyde concentration and hair cortisol and 
total count of CD144+ microvesicles, weak 
correlations between CD62e+ endothe-
l ial microvesicles and diastolic blood 
pressure (P=0.003, r=0.324), and systolic 
blood pressure (P=0.016, r=0.267). Predic-
tive model showed association between 
CD144+ microvesicle counts with cortisol 
and malondialdehyde concentrations also 
waist circumference.
Conclusions: In conclusion, our data and 
predictive model showed that the total 
count of CD144+ endothelial microvesicles 
were associated with stress related parame-
ters - cortisol and malondialdehyde concen-
trations; expression of CD62e in various 
populations of endothelial microvesicles 
were associated with increased diastolic 
and systolic blood pressure.
218. The metabolic profile of 
ischemic heart disease patients 
with or without previous MI by 
serum 1H NMR is similar
Tiina Titma1, Ulrich L. Günther2, 
Christian Ludwig3, Marika Pikta4, 
Galina Zemtsovskaja5, Min-Ji Shin, 
Margus Viigimaa1, 3, Risto Tanner1, Ago 
Samoson1,4
Department of Health Technologies, School of 
Information Technologies, Tallinn University of 
Technology
1 School of Information Technologies, Department 
of Health Technologies, Tallinn University of 
Technology, Tallinn, Estonia; 2 HWB-NMR, Institute 
of Cancer and Genomic Sciences, University of 
Birmingham, Birmingham, UK; 3 North Estonia 
Medical Centre, Tallinn, Estonia; 4 Department of 
Physics, University of Warwick, UK
Ischemic heart disease (IHD) is the most 
common cause of death in the world. 
Metabolic profiling is an innovative and 
reliable new method to detect more sensi-
tive biomarkers identifying altered health 
conditions specifically among the variety 
of patients with different risk factors. We 
evaluated the metabolic profile of filtered 
serum of IHD patients (ICD10 codes I20 
and I25.2) using proton nuclear magnetic 
resonance spectroscopy (NMR).
The filtered venous serum from age 
and gender matched IHD patients ICD10 
coded I20 (n=12), I25.2 (n=6) and control 
individuals (n=18) were analyzed using 
one-dimensional proton nuclear magnetic 
resonance (1H NMR) spectroscopy. These 
spectra were used for metabolic profiling 
and concentration calibration (Chenomx 
Inc) followed by statistical analysis using 
one-way ANOVA and principal component 
analysis (PCA).
Chemometrics analysis showed a signif-
icant distinction between the patients and 
control individuals. The IHD patients were 
exemplified by the increased concentra-
tion of acetylacetate, choline, pyruvate, 
betaine, formate and by the decreased 
concentration of alanine, creatine, glycine, 
histidine, lactate, proline, urea and other 
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biomolecules. The major implications 
found in the serum of IHD patients are 
related to energy metabolism and poten-
tially altered microbiome.
PCA of 1H NMR detected serum metab-
olites exhibit a significant difference of 
IHD patients and control individuals. These 
data demonstrate that metabolomics 
approach may be useful for the early detec-
tion of IHD, for detection of synergistic 
pathways involved in the development of 
altered health conditions, and molecular 
understanding of particular health condi-
tion. The differences of the detected meta-
bolic profile of ischemic patients with or 
without previous myocardial infarction 
appear to be minor.
This relatively inexpensive, non-inva-
sive and reproducible approach may be 
useful for the molecular understanding 
and early prevention of IHD, improvement 
of surveillance and therapy. The study 
emerge the need for future investiga-
tions using larger cohort and possible 
longitudinal sight.


